Author index

A

Aanstoot, H.J. 436
Abraham, R.R. 889
Abumrad, N.N. 357
Adamson, U. 287
Agius, L. S34
Akanuma, Y. 261
Akazawa, S. 748
Åkerblom, H.K. 70
Akkan, A.G. 505
Alberetto, M. 294
Alford, F.P. 399
Almdal, T. 331
Altahir, H. 645
Alvarsson, M. 367
Alvestrand, A. 1042
Amiel, S. S60
Andersen, P. 447
Andersen, P.K. 178
Andersson, A. 490
Anderton, C.D. 868
Andreani, D. 1093
Andreassen, T.T. 19
Andrews, J.W. 771
Aoki, Y. 913
Aperia, A. 414
Arnaiz-Villena, A. 475
Arner, P. 664, 1177
Arnqvist, H.J. 56, 104
Ashcroft, F.M. 619
Ashcroft, S.J.H. 619
Atkison, P. 884
Auinger, M. 425
Avogaro, A. 129, 372
Awata, T. 419

B

Baarsma, G.S. 555
Bach, J.F. 792
Bader, S. 712
Baird, J.D. 231
Bak, J.F. 777
Balkau, B. 39
Banga, J.D. 690
Bangstad, H.-J. 1165
Bargero, G. 851
Barker, D.J.P. 444, 595
Barrett-Connor, E. 173
Bartrons, R. 243
Basabe, J.C. 1159
Bauer, I. 77
Beck-Nielsen, H. 80
Beer, S.F. 277
Bell, G.I. 743
Bendtsen, T.F. 844
Bendtson, I. 898
Benschop, C. 202
Berger, M. 429, 649, 1187
Berne, C. 873
Bertera, S. 583
Besch, W. 608
Best, J.D. 399, 1055
Betsholtz, C. 26, 297
Beusekamp, B.J. 165
Binder, C. 898
Bindra, D.S. 224
Bingley, P.J. 32
Bischof, F. 1087
Bjaaland, T. 1020
Björk, E. 490
Black, I. S18
Blackman, J.D. 681
Blohmé, G. 56
Blom, L. 528, 1068
Blondel, H. 792
Blundell, T. S69
Boehm, B.O. 550
Boitard, C. 792, 924, 951, 1101
Bolinder, J. 664, 1042, 1177
Bone, A.J. 238
Bonifacio, E. 385
Borg, L.A.H. 939
Bornfeldt, K.E. 104
Bosi, E. 385
Bottazzo, G.F. 32, 385
Bouchard, C. 653
Boulton, A.J.M. 660, 1146
Bourey, R. 143, 1125
Boyle, P.J. 372
Bradish, G. 884
Brant, A.M. 304
Braulke, T. 216
Bravenboer, B. 690, 813
Brennan, G.M. 771
Brenner, H.-H. 1028
Bretzel, R.G. 550
Brichard, S.M. 522
Brinchmann-Hansen, O. 1049
Brown, M.B. 560
Brown, T.J. 380
Brownlee, M. 96
Bruce, D.G. 835
Brudzynski, K. 316
Bruining, G.J. 139, 436
Bruno, G. 851
Buren, T. van 813
Burkart, V. 1028
Burnett, M. 469
Busson, M. 951
Byrne, C.D. 192

C

Cahane, M. 398
Caillat-Zucman, S. 792
Cameron, N.E. 12, 946, 1011, 1113
Canela, J. 267
Capron, F. 224
Capron, L. 104
Capucchio, M. 1159
Carballo, E. 243
Cardoso, A.I. 1159
Carrascosa, J. 456
Carson, D.J. 452
Cassidy, D. 380
Castell, C. 267
Catterall, W. S23
Celsi, G. 414
Chakrabarti, S. 325, 560, 602
Chantelau, E. 191
Chantres, M.T. 583
Chatelain, P. 570
Chédin, P. 792
Cherian, P.V. 602
Chikuba, N. 748
Chisholm, D.J. 835
Chiu, K.C. 632
Christensen, N.J. 99
Christiansen, J.S. 1074
Christie, M.R. 380
Christopher, M.J. 399
Clark, P.M. 444, 469, 1170
Clark, P.M.S. 192
Claude, J.-R. 39
Colditz, G.A. 967
Cole, D.R. 231
Colle, E. 1118
Collins, V.R. 534
Corell, A. 475
Corrall, R.J.M. 991
Corriveau, M. 1118
Cotter, M.A. 12, 946, 1011, 1113
Cottrell, D.A. 676
Coulic, V. 505
Cox, B.D. 192
Cox, L. 469, 1170
Crace, C.J. 939
Crepin, K. 243
Crosby, S.R. 868
Cryer, P.E. 372
Cusin, I. 310
Czernichow, P. 577

D

Dahl-Jørgensen, K. 1165
Dahlquist, G. 528, 671, 980, 1068
Damsbo, P. 80
Danielsen, R. 880
Davies, J.A. 863
Day, N.E. 192
De Hertogh, R. 406
Dean, B.M. 385
DeFronzo, R.A. 389
Deijnen, J.H.M. van 735
Del Maschio, A. 1002
Del Prato, S. 310
Delcourt, J. 406
Deschamps, I. 951
Desoye, G. 45
Després, J.-P. 653
Diderholm, H. 249
Dines, K. 946
Dollinger, M. 1133
Donker, A.J.M. 555
Doormaal van, J.J. 165
Dorka, B. 589
Dorman, J.S. 583
Dosch, H.-M. 985
Dowse, G.K. 534, 632
Drykoningen, C.E.M. 139
Dubois, F. 577
Ducimetière, P. 464
Dullaart, R.P.F. 165
Duner, E. 129
Dunger, D.B. 542
Dunlop, M.E. 499
Durand, A. 570
Dyerberg, J. 447

E

Edelstein, D. 96
Edmonds, M.E. 148
Edmundson, A.W. 857
Efendic, S. 367
Eizirik, D.L. 924
Eklöf, A.-C. 414
Ekstrand, A. 1140
Elamin, A. 645
Elts, S.M. 818
Engström, Å. 26
Epstein, P.N. S23
Eriksson, H. 766
Eriksson, J. 143, 802, 1060, 1140
Eriksson, J.W. 510
Eriksson, L.S. 664
Eriksson, U.J. 517
Erkelens, D.W. 202, 813
Erkisson, J. 291
Eschwège, E. 39, 464

F

Fabiano de Bruno, L.E. 1159
Fagius, J. 873
Fainboim, L. 1159
Fajardy, I. 577
Federlin, K. 550
Ferguson, R.M. 676
Ferrannini, E. 697
Ferraro, R.T. 753
Ferrie, J.E. 785
Fitzgerald, A.P. 192
Flakoll, P.J. 357
Flier, J.S. 486
Flynn, M.D. 991
Flyvbjerg, A. 589
Fohlman, J. 249
Fontbonne, A. 39, 464
Fontvieille, A.M. 753
Foriers, A. 1080
Formanek, D. 425
Foster, A.V.M. 148
Francis, P.J. 238
Franssila-Kallunki, A. 962, 1140
Freund, P. 712
Friman, G. 249
Frisk, G. 249
Funk, B. 589
Fürnsinn, C. 116
Furuta, S. 913

G

Gade, J. 898
Gale, E.A.M. 32, 385
Gall, M.-A. 447

Author index

A

Aanstoot, H.J. 436
Abraham, R.R. 889
Abumrad, N.N. 357
Adamson, U. 287
Agius, L. S34
Akanuma, Y. 261
Akazawa, S. 748
Åkerblom, H.K. 70
Akkan, A.G. 505
Alberetto, M. 294
Alford, F.P. 399
Almdal, T. 331
Altahir, H. 645
Alvarsson, M. 367
Alvestrand, A. 1042
Amiel, S. S60
Andersen, P. 447
Andersen, P.K. 178
Andersson, A. 490
Anderton, C.D. 868
Andreani, D. 1093
Andreassen, T.T. 19
Andrews, J.W. 771
Aoki, Y. 913
Aperia, A. 414
Arnaiz-Villena, A. 475
Arner, P. 664, 1177
Arnqvist, H.J. 56, 104
Ashcroft, F.M. 619
Ashcroft, S.J.H. 619
Atkison, P. 884
Auinger, M. 425
Avogaro, A. 129, 372
Awata, T. 419

B

Baarsma, G.S. 555
Bach, J.F. 792
Bader, S. 712
Baird, J.D. 231
Bak, J.F. 777
Balkau, B. 39
Banga, J.D. 690
Bangstad, H.-J. 1165
Bargero, G. 851
Barker, D.J.P. 444, 595
Barrett-Connor, E. 173
Bartrons, R. 243
Basabe, J.C. 1159
Bauer, I. 77
Beck-Nielsen, H. 80
Beer, S.F. 277
Bell, G.I. 743
Bendtsen, T.F. 844
Bendtson, I. 898
Benschop, C. 202
Berger, M. 429, 649, 1187
Berne, C. 873
Bertera, S. 583
Besch, W. 608
Best, J.D. 399, 1055
Betsholtz, C. 26, 297
Beusekamp, B.J. 165
Binder, C. 898
Bindra, D.S. 224
Bingley, P.J. 32
Bischof, F. 1087
Bjaaland, T. 1020
Björk, E. 490
Black, I. S18
Blackman, J.D. 681
Blohmé, G. 56
Blom, L. 528, 1068
Blondel, H. 792
Blundell, T. S69
Boehm, B.O. 550
Boitard, C. 792, 924, 951, 1101
Bolinder, J. 664, 1042, 1177
Bone, A.J. 238
Bonifacio, E. 385
Borg, L.A.H. 939
Bornfeldt, K.E. 104
Bosi, E. 385
Bottazzo, G.F. 32, 385
Bouchard, C. 653
Boulton, A.J.M. 660, 1146
Bourey, R. 143, 1125
Boyle, P.J. 372
Bradish, G. 884
Brant, A.M. 304
Braulke, T. 216
Bravenboer, B. 690, 813
Brennan, G.M. 771
Brenner, H.-H. 1028
Bretzel, R.G. 550
Brichard, S.M. 522
Brinchmann-Hansen, O. 1049
Brown, M.B. 560
Brown, T.J. 380
Brownlee, M. 96
Bruce, D.G. 835
Brudzynski, K. 316
Bruining, G.J. 139, 436
Bruno, G. 851
Buren, T. van 813
Burkart, V. 1028
Burnett, M. 469
Busson, M. 951
Byrne, C.D. 192

C

Cahane, M. 398
Caillat-Zucman, S. 792
Cameron, N.E. 12, 946, 1011, 1113
Canela, J. 267
Capron, F. 224
Capron, L. 104
Capucchio, M. 1159
Carballo, E. 243
Cardoso, A.I. 1159
Carrascosa, J. 456
Carson, D.J. 452
Cassidy, D. 380
Castell, C. 267
Catterall, W. S23
Celsi, G. 414
Chakrabarti, S. 325, 560, 602
Chantelau, E. 191
Chantres, M.T. 583
Chatelain, P. 570
Chédin, P. 792
Cherian, P.V. 602
Chikuba, N. 748
Chisholm, D.J. 835
Chiu, K.C. 632
Christensen, N.J. 99
Christiansen, J.S. 1074
Christie, M.R. 380
Christopher, M.J. 399
Clark, P.M. 444, 469, 1170
Clark, P.M.S. 192
Claude, J.-R. 39
Colditz, G.A. 967
Cole, D.R. 231
Colle, E. 1118
Collins, V.R. 534
Corell, A. 475
Corrall, R.J.M. 991
Corriveau, M. 1118
Cotter, M.A. 12, 946, 1011, 1113
Cottrell, D.A. 676
Coulic, V. 505
Cox, B.D. 192
Cox, L. 469, 1170
Crace, C.J. 939
Crepin, K. 243
Crosby, S.R. 868
Cryer, P.E. 372
Cusin, I. 310
Czernichow, P. 577

D

Dahl-Jørgensen, K. 1165
Dahlquist, G. 528, 671, 980, 1068
Damsbo, P. 80
Danielsen, R. 880
Davies, J.A. 863
Day, N.E. 192
De Hertogh, R. 406
Dean, B.M. 385
DeFronzo, R.A. 389
Deijnen, J.H.M. van 735
Del Maschio, A. 1002
Del Prato, S. 310
Delcourt, J. 406
Deschamps, I. 951
Desoye, G. 45
Després, J.-P. 653
Diderholm, H. 249
Dines, K. 946
Dollinger, M. 1133
Donker, A.J.M. 555
Doormaal van, J.J. 165
Dorka, B. 589
Dorman, J.S. 583
Dosch, H.-M. 985
Dowse, G.K. 534, 632
Drykoningen, C.E.M. 139
Dubois, F. 577
Ducimetière, P. 464
Dullaart, R.P.F. 165
Duner, E. 129
Dunger, D.B. 542
Dunlop, M.E. 499
Durand, A. 570
Dyerberg, J. 447

E

Edelstein, D. 96
Edmonds, M.E. 148
Edmundson, A.W. 857
Efendic, S. 367
Eizirik, D.L. 924
Eklöf, A.-C. 414
Ekstrand, A. 1140
Elamin, A. 645
Elts, S.M. 818
Engström, Å. 26
Epstein, P.N. S23
Eriksson, H. 766
Eriksson, J. 143, 802, 1060, 1140
Eriksson, J.W. 510
Eriksson, L.S. 664
Eriksson, U.J. 517
Erkelens, D.W. 202, 813
Erkisson, J. 291
Eschwège, E. 39, 464

F

Fabiano de Bruno, L.E. 1159
Fagius, J. 873
Fainboim, L. 1159
Fajardy, I. 577
Federlin, K. 550
Ferguson, R.M. 676
Ferrannini, E. 697
Ferraro, R.T. 753
Ferrie, J.E. 785
Fitzgerald, A.P. 192
Flakoll, P.J. 357
Flier, J.S. 486
Flynn, M.D. 991
Flyvbjerg, A. 589
Fohlman, J. 249
Fontbonne, A. 39, 464
Fontvieille, A.M. 753
Foriers, A. 1080
Formanek, D. 425
Foster, A.V.M. 148
Francis, P.J. 238
Franssila-Kallunki, A. 962, 1140
Freund, P. 712
Friman, G. 249
Frisk, G. 249
Funk, B. 589
Fürnsinn, C. 116
Furuta, S. 913

G

Gade, J. 898
Gale, E.A.M. 32, 385
Gall, M.-A. 447

Galuska, D. 26
Genovese, S. 385
Gerbitz, K.D. 183
Gerbitz, K.-D. 1181
Gibbs, E.M. 304
Gilcrease, M.Z. 160
Gispen, W.H. 813
Giugliano, D. 698
Glück, M. 550
Gnudi, L. 129
Goday, A. 267
Goodnow, C.C. S49
Gordon, C. 868
Gorus, F. 719
Gorus, F.K. 1080
Gould, G.W. 304
Grabensee, B. 1187
Grant, P.J. 863
Green, A. 178
Greenbaum, C.J. 798
Greene, D.A. 560
Gries, F.A. 828, 1099
Grill, V. 367
Groop, L. 291, 802, 962, 1140
Groop, L.C. 143
Gu, X.F. 577
Gu, X.-H. 889
Gupta, R.S. 316
Gutierrez-Lopez, M.D. 583

H

Haffner, S.M. 697
Hagström-Toft, E. 664
Hakura, A. 614
Hales, C.N. 192, 444, 469, 595
Hamers, F.P.T. 813
Hanafusa, T. 614
Hansen, K.W. 1074
Hanssen, K.F. 1049, 1165
Häring, H.U. 456, 712
Harris, N.D. 155
Hartmann, H. 216, 932
Harvey, J.N. 857
Hashimoto, N. 639
Hawa, M. 277
Hayes, J.R. 771
Hehmke, B. 608
Heinemann, L. 649
Helgason, T. 880
Hellerström, C. 1
Hendriksen, P.H. 690
Hennekens, C.H. 967
Henquin, J.C. 522
Henquin, J.-C. 907
Henry, M.L. 676
Henry, W.R. 771
Hering, B. 550
Herold, K.C. S49
Hill, J.O. 357
Hilsted, J. 99
Hjemdahl, P. 873
Hofmann, H.H. 45
Hollenstein, U. 116
Hommel, E. 447
Hoogenberg, K. 165
Hoover, R.L. 160
Hopmeier, P. 77
Hors, J. 951
Hosaka, Y. 730
Hother-Nielsen, O. 80
Houwing, H. 917
Howell, S.L. 1020
Hubbard, R. S69
Hübinger, A. 828
Hue, L. 243
Hyöty, H. 63

I

Ibbotson, S.H. 863
Imam, S.Z. 452
Imura, H. 1035
In 't Veld, P.A. 272
In't Veld, P. 719
Iori, E. 129
Irsigler, K. 425
Ishida, H. 1035
Ismail, B. 645
Iwamoto, Y. 419

J

Jaffa, A.A. 857
James, D.E. S41
Janjic, D. 482
Janus, E.D. 1055
Jarrett, R.J. 192
Jeanrenaud, B. 310
Jenkins, A.B. 208
Jenkins, A.J. 1055
Jenkins, J.G. 452
Jenner, M. 884
Jensen, B. 447
Johansson, B.-L. 121, 1151
Johansson, U. 664
Johnson, K.H. 26, 297
Johnston, G.D. 771
Joner, G. 1049
Jones, P.M. 1020
Jongkind, J.F. 436
Jorde, R. 958
Juan, D.de 475

K

Kaarsalo, E. 760
Kadowaki, H. 261
Kadowaki, T. 261
Kahn, B.B. 304
Kahn, C.R. 109
Kahri, J. 347
Källén, B. 671
Kämpe, O. 490
Kanazawa, Y. 419
Kappelle, A.C. 813
Kaprio, E.A. 70
Kaprio, J. 1060
Karjalainen, J. 985
Karlsson, F.A. 490
Karvonen, M.J. 760
Kasuga, M. 261
Kato, S. 1035
Kawasaki, E. 748
Kellerer, M. 712
Kemmer, F.W. 1187
Kesäniemi, Y.A. 1060
Kessler, U. 589
Keymeulen, B. 719, 1080
Kiess, W. 589
Kim, H. 261
Kivinen, P. 760
Kiyosawa, K. 913
Klein, D.J. S8
Klöppel, G. 272
Kneteman, N.M. 89
Knight, L.T. 534
Knowles, W. 996
Kofoed-Enevoldsen, A. 1165
Köhler, E. 608
Kohner, E.M. 190
Kohonen-Corish, M.R.J. 996
Koike, T. 1028
Koivisto, V. 347
Kolb-Bachofen, V. 331, 796
Kolb, H. 796, 1028
Kollind, M. 287
Kono, N. 614
Koranyi, L. 143, 1125
Körner, A. 414
Kortlandt, W. 202
Koskenvuo, M. 1060
Koskinen, L. 63
Kowluru, A. 624
Kowluru, R.A. 624
Kraegen, E.W. 835
Kranenburg, G. 436
Krentz, A.J. 1170
Krijger, R.R.de 436
Kröncke, K.-D. 331
Krook, A. 486
Kurose, T. 1035
Kusunoki, M. 208
Kuzuya, T. 419

L

Lafferty, K.J. 436
Lahrmann, H. 425
Laitinen, J. 340
Landin-Olsson, M. 980, 1068
Länsimies, E. 340
Lantos, J. S60
LaPorte, R.E. 139
Larkins, R.G. 499
Larsson, B. 766
Laudadio, C. 560
Leclercq-Meyer, V. 505
Lee, W.C. 973
Lefèbvre, P.J. 494, 1188
Leighton, B. 801
Leinikki, P. 63
Lemieux, S. 653
Lernmark, Å. 1068, 1096
Leslie, R.D.G. 277
Levy, D.M. 889
Levy, J.C. 469
Lévy-Marchal, C. 577
Liener, K. 116
Lillioja, S. 753
Lin, R.S. 973
Linde, B. 1151
Linné, T. 414
Lins, P.-E. 287
Lisato, G. 310
Lithner, F. 56
Littorin, B. 56
Liu, D. 287
Lledo, G. 475
Lloveras, G. 267
Lo, S.S.S. 277
Lönnroth, P. 510
Lounamaa, R. 70
Love, A. 946
Lucke, S. 608

M

Macdonald, I.A. 287
Mackay, I.R. 996
Madsen, O.D. 272
Maeda, Y. 748
Makarovic, M. 1002
Makino, H. 639
Malaisse-Lagae, F. 505
Malaisse, W.J. 505
Mandrup-Poulsen, T. 331
Mangili, R. 1002
Manson, J.E. 967
Maran, A. 129
Marcelli-Barge, A. 951
Marchand, J. 505
Marescotti, C. 129
Marmot, M.G. 785
Marshall, S.M. 1074
Martin, L.L. 857
Martin-Villa, J.M. 475
Martinez-Laso, J. 475
Martinez, V. 316
Mathaei, S. 712
Matsuda, A. 419
Matsukura, S. 291
Matthews, D.R. 32, 542, 696
Mau Pedersen, M. 1074
Mayfield, R.K. 857
McClure, B.G. 452
McCoid, S.C. 304
McDermott, B.J. 771
McGrath, L.T. 771
McIntyre, M. 231
McKeigue, P.M. 785
McNally, J.M. 385
McVeigh, G.E. 771
Meijer, S. 165
Merkle, M. 425
Meyer-Alber, A. 216
Meyerhoff, C. 1087
Minei, A. 698
Miola, M. 129
Miralpeix, M. 243
Mitchell, B.D. 697
Mitchell, R.H. 452
Miyagawa, J. 614
Miyamoto, T. 748
Miyazaki, Y. 261
Miyazato, M. 291
Mizisin, A. S18
Møller, N. 777
Moatti-Sirat, D. 224
Moberg, E. 287
Mogenet, A. 951
Mogensen, C.E. 1074
Moller, D.E. 486
Möller, E. 283
Momomura, K. 261
Morales, P. 475
Morgan, R. 486
Moriuchi, R. 748

Mortensen, K. 178
Mota, A.H. 1159
Mueckler, M. 143, 1125
Mühlbacher, C. 456
Mühlen, H. 828, 1099
Mühlhauser, I. 429
Mulder, A.L.M. 139
Murray, H.J. 660
Mushack, J. 456

N

Nadeau, A. 653
Nagataki, S. 748
Nahoul, K. 173
Nakagawa, C. 614
Nakajima, H. 614
Nakazato, M. 291, 802
Nattrass, M. 1170
Nauta, J.J.P. 555
Nerup, J. 331
Nielsen, F. 447
Nishi, S. 743
Nissinen, A. 760
Nosadini, R. 129
Nossal, G.J.V. S49
Nowotny, P. 116
Nozaki, O. 639
Nyengaard, J.R. 844
Nyström, L. 56, 1068

O

Ørskov, C. 701
Ørskov, H. 589
Østerby, R. 803
Obermaier-Kusser, B. 456
O'Brien, T.D. 297
Odawara, M. 261
O'Dorisio, T.M. 676
Oey, P.L. 690
Oguchi, H. 913
Ohlson, L.-O. 766
Ohtaka, M. 730
Ohtani, T. 261
Okamoto, Y. 1035
Oklek, K. 1173
Okuno, S. 748
Olerup, O. 283
Olgemöller, B. 183
Olsson, P.O. 56
O'Meara, N.M. 681
Onaya, T. 730
Ongemba, L.N. 522
Oosawa, Y. 619
O'Rahilly, S. 486
Orgiazzi, J. 570
Osei, K. 676
Osmond, C. 444
Östman, J. 56
Ottolander, G.J.H.den 555
Oxlund, H. 19

P

Packard, C.J. 347
Paepe De, M.E. 1118
Pagano, G. 851
Pal, B.R. 542
Palmer, J.P. 798, 1068
Pampfer, S. 406
Papoz, L. 173
Parkkonen, P. 63
Parving, H.-H. 447
Pascoe, W.S. 208
Pearson, J.D. 1020
Pedersen, O. 777
Pekkanen, J. 760
Peltonen, L. 254
Pennock, C.A. 991
Permutt, A.M. 143
Permutt, M.A. 632, 1125
Persaud, S.J. 1020
Persson, B. 414
Persson, L.Å. 528
Petersen, J. 570
Pfeiffer, E.F. 1087
Phillips, J.W. 818
Phillips, P.E. 542
Pierpoint, T. 785
Pipeleers, D.G. 719, 1080
Pisu, E. 851
Poitout, V. 224
Polak, B.C.P. 555
Polak, J.M. 889
Pollare, T. 873
Polonsky, K.S. 681
Pongratz, D. 456
Pontiroli, A.E. 294
Poskus, E. 1159
Pozza, G. 294, 1002
Pozzilli, P. 1093
Prashar, A. 560
Pregant, P. 77
Preziosi, P. 173
Province, M.A. 632
Prud'homme, D. 653
Pyke, D.A. 277

Q

Quatraro, A. 698
Quetin, C. 398

R

Rabinovitch, A. 89, 409
Rajotte, R.V. 89
Rankel, G. 1002
Ravussin, E. 753
Reach, G. 224, 398
Rees, A. 486
Reimers, J. 331
Rett, K. 712
Reunanen, A. 70, 1060
Rice, D.E. 357
Richter, W. 550
Rijn van, H.J.M. 202
Rimm, E.B. 967
Rising, R. 753
Robert, J.-J. 951
Robertson, R.P. S8
Robertson, S. 12, 1113
Robin, D. 406
Robinson, S. 444
Roden, M. 116
Roger, M. 173
Rollins, M.D. 452
Romanov, K. 1060
Rosa, N.De 698
Rosner, B. 967
Ross, R. S34
Rossing, P. 447
Rousseau, G.G. 243
Rowley, M.J. 996
Ryan, E.A. 89

S

Saack, A. 777
Sager, G. 958
Saint-Paul, M. 173
Sakura, H. 261
Saloranta, C. 1140
Sandler, S. 924
Sanjeevi, C.B. 283
Santamaria, J.D. 1055
Santiago, J.V. 372
Sarvetnick, N. S1
Saukkonen, T. 985
Savilahti, E. 980, 985
Sawicki, P.T. 649
Schalin-Jäntti, C. 143, 1140
Scherbaum, W. 570
Scherbaum, W.A. 550
Schernthaner, G. 77, 904
Scherstén, B. 56
Schilfgaarde, R.van 735, 917
Schleicher, E.D. 183
Schlosser, M. 608
Schmid, R. 1133
Schmitz, O. 777
Schnack, Ch. 77
Schnack, CH. 904
Schnell Landström, A. 939
Scholz, R. 712
Schravendijk, C.F.H.Van 1080
Schulz, L.O. 753
Schusdziarra, V. 1133
Schwaabe, S. 183
Seemayer, T.A. 1118
Seffer, E. 456
Segurado, O.G. 475
Seino, Y. 1035
Seißler, J. 550
Serjeantson, S. 632
Serjeantson, S.W. 996
Serrano-Rios, M. 583
Seshiah, V. 283
Shah, S.D. 372
Shapiro, E.T. 681
Shepherd, J. 347
Shepherd, P.R. 304
Shimada, F. 639
Shiomi, K. 291
Shizuru, J.A. S1
Shows, T.B. 743
Siegler, M. S60
Signore, A. 1093
Siitonen, O. 340
Sima, A.A.F. 325, 560, 602
Simmons, D.A. 725
Simon, D. 173
Simpson, I. 409
Sironi, S. 1002
Sjöberg, S. 121
Slama, G. 398
Sleeman, M.W. 399
Sluiter, W.J. 165
Smith, L. 372
Smith, U. 510
Smythe, G.A. 835
Sodoyez, J.-C. 1080
Southgate, J.L. 238
Speizer, F.E. 967
Springall, D.R. 889
Sroczynski, J.W. 1173
Stampfer, M.J. 967
Starke, A. 649
Steele, J.S. 1055
Stefanutti, A. 570
Stehouwer, C.D.A. 555
Steiner, D.F. S41
Stengård, J. 1060
Stengård, J.H. 760
Stenvinkel, P. 1042
Stern, M.P. 697
Sternberg, F. 1087
Stevens, M.J. 148
Stiller, C. 884
Stoffel, M. 743
Storlien, L.H. 208, 835
Strandell, E. 924
Stratton, I.M. 696
Strik, R.van 436
Strojek, K. 1173
Strubbe, J.H. 917
Strynadka, K. 409
Stümpel, F. 932
Sturis, J. 681
Suarez, W.L. 409
Sulzer, M. 429
Sundkvist, G. 1068
Sundsfjord, J. 958
Suylichem, P.T.R.van 917
Suzuki, Y. 639
Svärdsudd, K. 766
Svendsen, A.J. 178
Swenne, I. 193, 939

T

Taberner, J.L. 267
Taira, M. 639
Takahashi, Y. 261
Takao, Y. 748
Takeda, J. 743
Takino, H. 748
Tannous, W.N. 1118
Tappaz, M. 570
Tarui, S. 614
Taskinen, M.-R. 347
Tawata, M. 730
Taylor, S.I. 261
Teng, H. 719
Terenghi, G. 889
Tesfaye, S. 155
Tesi, R.J. 676
Theilgaard, A. 898
Thévenot, D.R. 224
Thibult, N. 464
Thivolet, CH. 570
Thomas, P.D. 409
Thorsson, A.V. 880
Tibblin, G. 766
Tichet, J. 577
Tienari, P.J. 254

Tiengo, A. 129, 310
Timsit, J. 792
Tippmer, S. 712
Tomita, K. 614
Torres, C. G. 1049
Tremblay, A. 653
Tresserras, R. 267
Trucco, M. 583
Tsigos, C. 868
Tsuda, K. 1035
Tsuji, K. 1035
Tsuura, Y. 1035
Tuomilehto, J. 70, 254, 760, 1060
Tuomilehto-Wolf, E. 70, 254
Turk, J. 1125
Turner, R. C. 469
Turner, R. L. 696
Tuvemo, T. 249, 645

U

Unger, E. 517
Ungerstedt, U. 664, 1177
Usami, M. 1035
Uusitupa, M. 340

V

Vaag, A. 80
Vaaler, S. 958
Vaandrager, G. J. 139
Valerio, A. 129
Valk, H. W. de 904
Van Cauter, E. 681
Vanderheyden, I. 406
Vanninen, E. 340
Vavassori, C. 583
Vea, H. 958
Verkerk, A. 436
Vetri, M. 719
Veves, A. 660, 1146
Vialettes, B. 570
Vicario, J. L. 475
Vierhapper, H. 116
Villanove-Robin, F. 398
Virtala, E. 70
Vogt, B. 456
Vorberg, E. 699
Vos-Scheperkeuter, G. H. 735
Vuolo, A. 851

W

Wagner, G. 632
Wagner, R. 385
Wahren, J. 121, 1151
Waldhäusl, W. 116
Walker, M. G. 1146
Wallberg-Henriksson, H. 26
Walmsley, D. 863
Walton, R. J. 444
Wang, T. W. N. 192
Wanke, T. 425
Ward, J. D. 155
Warnet, J.-M. 39
Warnock, G. L. 89
Waterfall, M. 231
Waters, P. J. 991
Watkins, P. J. 2, 148
Weatherall, D. S1
Weigert, N. 1133
Weiss, M. A. S69
Weiss, P. A. M. 45
Welin, L. 766
Wentzel, L. S. 357
Westermark, P. 26, 297
White, A. 868
Wibell, L. 56
Widén, E. 143, 1140
Wieneke, G. H. 690
Wilkin, T. J. 187, 238, 798
Willett, W. C. 967
Williams, A. C. 1170
Williams, A. J. K. 32
Williams, D. R. R. 192
Williams, K. A. 818
Wilson, G. S. 224
Wilson, R. M. 155
Winegrad, A. I. 725
Witt, S. 608
Wogensen, L. D. 331
Wollheim, C. B. 482
Wolters, G. H. J. 735, 917
Wong, H. C. 818
Wong, J. S. K. 190

X

Xiang, K. 743

Y

Yamamoto, H. 748
Yamamoto, K. 614
Yamazaki, A. 624
Yanagisawa, Y. 913
Yassin, N. 550
Yazaki, K. 913
Yazaki, Y. 261
Yokota, A. 748
Yoshida, S. 639
Young, M. J. 660, 1146
Young, R. J. 868
Yutsudo, M. 614

Z

Zavala, A. V. 1159
Zellenrath, P. 555
Zerbini, G. 1002
Zhang, F. 272
Zhang, W.-X. 602
Zhang, Y. 224
Ziegler, B. 608
Ziegler, D. 828, 1099
Ziegler, M. 608
Zier, H. 1087
Zierath, J. R. 26
Zimmet, P. 996
Zimmet, P. Z. 534, 632
Ziora, D 1173
Zoppini, G. 109
Zwick, H. 425

Subject Index

KEY: A = Abstract in Supplement 1; b = Book review; c = Correspondence; r = Review or Debate; S = Supplement 2; w = Workshop report

A

Acarbose */see a*-glucosidase inhibitor/
Adenosine – vasodilator effect – glucose concentration and 725
Adhesion – */see also* Monocyte/
– molecule – circulating – diabetes – Type 1 A 33
Adipocyte – membrane – glucagon & GLP-1(7–36) amide receptors A 76
– metabolism – glucose feeding, effect of A 102
Adipose tissue */see also* Fat/
– insulin, effect of – catecholamine interaction 664
– lipogenic enzyme expression – glucose, effect of A 17
– metabolism 664
– – sympathetic nervous system, effect of A 101
– microdialysis 664
Adolescence – diabetes – Type 1 – retinopathy 1049
Adrenaline – capillary permeability, effect on 99r
– glycogen metabolism, effect on – skeletal muscle 399
– ketogenic effect – insulin and 129
– vasoconstrictor effect – glucose concentration and 725
Adrenoceptor – α_2 – blocking agent – SL 84.0414 – metabolic effects A 104
Aetiologic fraction 475
AIDSPIT (Artificial Insulin Delivery Systems Pancreas & Islet Transpltn Study Group)
– EASD News Section 25 *Following page* 594w
Albert Renold Fellowship 1992 *Following page* 1010
Albumin – excretion rate */see also* Microalbuminuria/
– – insulin, effect of 99r
Albuminuria – diabetes – aminoguanidine, effect of – rat 96
– sorbinil, effect of – streptozotocin-diabetic rat 414
Alcohol – mortality – diabetes 39
Aldose reductase – aorta – streptozotocin-diabetic rat 1011
– expression – calf pulmonary artery endothelial cell 730
– – retinal epithelial cell A 139
– inhibitor – (4-amino-2–6-dimethylphenylsulphonyl)nitromethane A 203
– – lens epithelial cell myo-inositol, effect on A 104
– – ponalrestat A 203
– – retina, effect on – galactose-fed dog A 143
– – sorbinil 414
– – TAT – diabetic neuropathy, effect on A 151
– – vasomotor deficiency in diabetic rat, effect on 1011
– – WAY-121,509 A 49
– – zopolrestat – renal hyperfiltration – diabetes rat A 148
Alloxan – diabetes – protection – glutathione isopropyl ester A 201
a-glucosidase inhibitor – acarbose – BB rat – neuropathy 325
– – multicentre trial A 15
– miglitol A 15
Aminoguanidine – albuminuria, effect on 96
– collagen glycation, effect on 19
– diabetic neuropathy, effect on – streptozotocin-diabetic rat 946
– lipoperoxidation end-products, effect on A 55
Amylin 297r
– antibodies – spontaneous 1080
– expression, islet A 57
– – GLUT-2 expression and 1125
– gene – regulation A 85
– glucose transport, effect on – skeletal muscle 26
– human – transgenic mouse, in – localisation in pancreas A 81
– infusion – intraportal – insulin resistance in A 89
– insulin secretion, effect on A 115
– insulinoma, in A 118, A 119
– liver, effect on 116
– pancreas – human fetal 272
– plasma – relatives of Type 2 diabetics 291, 801
– secretion – obesity A 115
Anaerobic threshold – exercise & diet, effect of – Type 2 diabetes 340
Angiotensin – II – vasoconstrictor effect – glucose concentration and 725
– converting enzyme inhibitor – diabetes A 93
– – lisinopril 12
– – – microalbuminuria A 148
– – muscle, effect on – diabetic rat 12
– – nerve, effect on – diabetic rat 12
Antiandrogen – flumetanide – insulin resistance, effect on A 86
Antibody – advanced glycation endproduct – HLA A 208
– amylin auto- 1080, A 209
– autonomic nervous tissue – diabetic neuropathy A 156
– *β*-lactoglobulin – diabetes – Type 1 A 208
– – risk of diabetes – Type 1 980, A 24
– bovine serum albumin – assay 985
– – diabetes – Type 1 985
– ganglioside – diabetes – Type 1 A 209
– glutamic acid decarboxylase – 64 & 67 A 50
– – assay A 50
– – – brain extract A 206
– – diabetes – Type 1 996
– – HLA 996, A 50
– – monoclonal A 51
– – pancreatic histology A 41
– – persistence – Type 1 DM A 209
– – prediction of diabetes Type 1 570
– insulin auto – assay – standardisation 798w
– – diabetes – secondary failure of tablet treatment 1159
– – insulin binding *in vivo*, effect on A 81
– – prediction of diabetes Type 1 1068
– – prevalence 570
– – relatives of Type 2 diabetics A 208
– islet-cell – antigen A 208
– – – ganglioside GM2–1 A 42, 380, 385, 490
– – childhood – Sardinia A 32
– – cytoplasmic – heterogeneity & selectivity 385
– – diabetes – gestational A 211
– – – Type 1 – HLA-DQ A 50
– – – Type 2 A 210
– – endocrine cells – diabetes – Type 1 A 209
– – gestational diabetes – subsequent IVGTT A 27
– – glutamic acid decarboxylase */see* Antibody – glutamic/
– – heterogeneity – diabetes – Type 1 792
– – insulinoma cell reactivity A 207
– – monoclonal – human A 42
– – – lack of betacytotoxicity *in vivo* 608
– – M_r 64,000 – prediction of Type 1 diabetes 550
– – – Type 1 diabetes A 209
– – – – longstanding 748
– – oscillatory insulin secretion 32
– – prediction of Type 1 diabetes 955, 1068
– – prevalence – childhood – France 570
– monoclonal – endocrine pancreas 436
Antidiabetic drug */see* Hypoglycaemic agent/
Aorta – Na^+/K^+ ATPase – glucose concentration, effect of 725
– rabbit intima-media preparation 725
– rat – streptozotocin-diabetic 1011
Apolipoprotein – A – plasma – microalbuminuria – Type 2 diabetes 1055
– A-I – metabolism – Type 1 diabetes 347
– A-II – metabolism – Type 1 diabetes 347
– A-IV – Type 2 diabetes A 168
– B – lipoprotein synthesis regulation, role in A 17
– B – metabolism – glycation, effect of 202
– E – polymorphism – Type 2 diabetes & gender A 63
– polymorphism – coronary heart disease – diabetes A 64
Artery – carotid – atherosclerosis – diabetes A 96, A 95
Ascorbic acid – metabolism – renal and neural – BB rat A 11
Assay – immunoradiometric – proinsulin and products 469

Astrocyte – insulin effects – signal transduction – IGF comparison A 99
Atherogenesis S 34 w
Atrial natriuretic factor – plasma – hyperinsulinaemia, in 1042
Autocorrelation 32
Autoimmunity – anti-islet 1101 r
– cell-mediated – diabetes Type 1 A 213, A 215
– diabetes Type 1 187
– – follow-up study A 214
– function 187
– insulinoma-cell – passive transfer – NOD mouse A 23
– islet – diabetes – secondary failure of tablet treatment 1159
– tolerance diabetes – Type 1 S 49 w

B

B-cell, islet *[see also* Insulin – secretion; Islet*]*
– acetylcholine, effects of – Na^+ and Ca^{2+} A 100
– autoimmunity 1101 r
– Ca^{2+} – channel – types A 121
– – culture duration, effect of A 99
– – oscillation A 13
– – – cAMP synchronisation A 58
– – – Na^+/K^+ pump inhibition, effects of A 122
– – protein kinase C, effect of A 100, A 101
– – Type 1 diabetic serum, effect of A 58
– cell-mass – malnutrition in early life, effect of 939
– cellular & molecular biology S 41 w
– cytokine toxicity – free radicals involved 409, 796
– function – assessment – assay of proinsulin and products 469
– – diabetes Type 1 – at clinical onset A 124
– – – before onset 277
– – – – *Erratum* 1100
– glucokinase – microsatellite DNA polymorphism 743
– – – *Erratum* 1100
– glucose-unresponsive – leucine, stimulation by A 111
– granule – electron density A 125
– HLA expression – Class I – mumps virus 63
– HSP60 related protein – NOD mouse 316
– human – cell separation 436, A 119
– interleukin 1*b*, effect of 331
– K^+ channel – ATP-dependent – rundown A 121
– – ATP-dependent – trypsin, effect of A 117
– – Ca^{2+}-activated – assay – planar lipid bilayer 619
– – low-conductance – oscillations A 58
– membrane potential – Ca^{2+} fluxes, role of A 99
– MHC expression – Class II – antigen presentation? A 23
– mitochondrial metabolism A 116
– Na^+ channel – insulin secretion, inhibition of A 120
– platinum toxicity A 49
– protection *[see* Alloxan; Immunotherapy; Nicotinamide*]*
– regeneration – promoter – nicotinamide A 115
– replication – diabetes 193 r
– residual – identification by in-situ hypridisation A 80
– selective destruction *in vivo* – streptozotocin, mesenteric A 79
Basal metabolic rate – diabetes – Type 2 962
Bergman minimal model method 676
β-cell *[see* B-cell, islet*]*
β-hydroxybutyrate *[see* Ketones*]*
Bladder function – diabetes – ganglioside derivatives, effect of A 151
Blood – arterialised venous – glucose sampling 287
– coagulation *[see* Haemostasis*]*
– flow – cerebral – diabetes A 173
– – Charcot foot 148
– – diabetic foot – laser doppler study A 159
– – diabetic neuropathy 2 r
– – nerve 1113
– – – diabetic neuropathy, role in 1146, 155
– group – maternal-child incompatibility – diabetes Type 1 risk factor 671
– pressure – ambulatory monitoring 1074
– – ambulatory monitoring – microalbuminuria – diabetes A 163
– – circadian variation – diabetic nephropathy 1074
– – diurnal rhythm – diabetes A 154
– – von Willebrand factor and 555
Body – composition – Pima Indians 753
– fat distribution *[see* Fat – distribution*]*
– weight – diabetes incidence and – Sweden 56
Bone – mineral density *[see also* Osteoporosis*]*
– – diabetes A 191, A 192
– turnover – diabetes A 192
Brain – glucose transporter 304
– pericyte – growth – glucose, effect of 818

C

C-peptide – actions – muscle, exercising 1151
– actions – muscle, exercising A 65
– glomerular function, effect on 121
– plasma – arginine, response to 367
– release – insulin release, relation to A 115
– renal function, effect on A 146
– secretion – diabetes – Type 2 – normoglycaemia duration, effect of A 105
Cadherin – islet-cell – molecular cloning A 57
Calcitonin – gene – related peptide *[see* CGRP*]*
Calorimetry – indirect 753
Capillary permeability 99 r
– islet – diabetic BB rat 1118
– protein A-gold immunocytochemistry 1118
Cardiovascular – risk factor – Paris prospective study 464
Care of diabetes *[see* Diabetes – care*]*
Catalonia – diabetes – Type 1 267
Cataract – diabetes – lipid peroxidation in A 46
Catecholamine – diabetes Type 2, effects in 835
CGRP (Calcitonin gene related peptide) 297 r
– degradation – skeletal muscle A 18
Charcot arthropathy – selective neuropathy 148
Cheiroarthropathy – diabetic – microangiopathy, association with? A 191
Cholecystokinin – receptor – subtypes – islet A 85
Cholesterol – synthesis – hyperinsulinaemia, effect of A 63
– transport – reverse – Type 1 diabetes A 64
Chromogranin A – converting enzyme – endopeptidase A 107
Cirrhosis – fructose as carbohydrate source A 107
Clamp – euglycaemic A 28
– – hyperinsulinaemic 777
– – – *fa/fa* rat – vanadate 522
– – – human 357
– – – persisting endogenous glucose prodn A 7
– – – rat 310
– – – sympathetic nervous response 873
– – rat – IGF-II effect 932
– non-esterified fatty-acid 372
Claude Bernard Lecturer 1992 – Bennett, PH *Following page* 1010
Coeliac disease – diabetes – Type 1 A 211
Cognitive function – hypoglycaemia – nocturnal 898
– – previous glycaemia, effect of 828
– Reaven's syndrome A 97
Collagen – glycation – aminoguanidine, effect of 19
– rat tail tendon – diabetes 913
– thermal stability – Vitamin E, effect of 913
Collagenase – islet isolation, use in 735
Complement – C4B – prediction of Type 1 diabetes in siblings 955
Complications of diabetes – lysosomal enzymes, plasma 991
– pulmonary function abnormalities 1173
– quality of care 429
– redox abnormalities, role of A 46
Computer – simulation – blood glucose response to exercise & diet A 164
Congenital malformation *[see* Teratogenesis*]*
Contraception – oral – risk of diabetes – Type 2 967
Cryopreservation – human islet 89
CSII *[see* Insulin – infusion – subcutaneous*]*
Cycle – ergometer test 425
Cyclosporin A – childhood diabetes 884
– insulin resistance A 98
– insulin secretion, effect on A 39
Cystic fibrosis – diabetes A 140
– – insulin secretion, early impairment of A 110

– glucose tolerance – prospective study A 141
Cytokine – islet toxicity – dorsal *vs.* ventral islets A 128

D

Dawn phenomenon A 195
– growth hormone deficiency, absence in 372
Denmark – diabetes incidence 178
Desferrioxamine – diabetes A 202
Dexamethasone – insulin response to arginine, effect on 367
Diabetes – care – delivery A 174
– – hospital admission – children A 176
– – quality – assessment 429, A 52
– – – improvement – Diabcare A 51
– – Sudan 645
– economics A 175
– malnutrition-related – genetic difference from Type 1 diabetes 283
– Textbook – Alberti, De Fronzo, Keen & Zimmet 1009b
– – Pickup & Williams 1009b
– Type 1 */see also* Islet; Mouse – NOD; Rat – BB/*
– – autoimmunity */see* Autoimmunity – diabetes/*
– – epidemiology */see* Epidemiology/*
– – genetics */see also* Genetics/*
– – – factors – environmental factors and 70
– – prediction */see* Prediabetes; Prediction/*
– – slowly-progressive A 210
– – treatment */see also* Dawn phenomenon; Insulin/*
– Type 2 */see also* Insulin – resistance; Reaven's syndrome/*
– – obesity – treatment A 195
– – pathogenesis 389r
– – – intrauterine and neonatal nutrition 595r
– – – thrifty phenotype hypothesis 595r
– – rat model 208
– – treatment */see also* Diet; Exercise; Hypoglycaemic agent/*
– – – exercise & diet 340
Diabetologia – circulation policy 1
Diacylglycerol – diabetic nephropathy, role in 499r
Diet – diabetes – European survey A 164
– – fatty acid – polyunsaturated – microalbuminuria 165
– – Type 2 – metabolic effects 777
– – – with exercise 340
– evaluation – barcode system A 165
– – diabetes – Type 2 A 165
– fat – fish oil – diabetes Type 2 – glucose turnover A 40
– – – *fa/fa* rat A 39
– – – lipid handling, effect on A 30, A 31, A 31
– – – – peroxidation A 40
– – – metabolic fate & obesity A 39
– – glucose transporter, effect on – rat A 30
– – incretin effect – diabetes – Type 2 A 31
– – insulin resistance, effect on – mouse A 49
– – – rat 208
– – monounsaturated A 31, A 40
– – muscle glucose update, effect on A 17
– – Ω_3 fatty acids */see* Diet – fat – fish oil/*
– – Ω_6 polyunsaturated fatty acids – glucose tolerance, effect on A 40
– fibre – glucose homeostasis, effect on A 165
– fish – coronary heart disease mortality A 166
– guidance by pocket computer system A 164
– haemodialysis – diabetes A 165
– maternal – diabetes Type 2 pathogenesis 595r
– meal frequency – diabetes – Type 2 A 166
– protein – restricted – renal function, effect on – diabetes A 148
– weight-reducing – glucose homeostasis A 166
DNA – damage – islet A 127
– mitochondrial – diabetes pathogenesis, role in? 1181r
DPSG (Diabetic Pregnancy Study Group *Following page* 192w

E

EASD – General Assembly (Suppl 1) I
– News Section *Following pages* 98, 192, 296, 398, 497, 594, 802, 906, 1010, 1100
– Study Group – Metabolism & Insulin Action Following p. 296
EASDEC (European Assoc'n for Study of Diabetic Eye Complic'ns) 190w
EASDEC *Following page* 398
EDESG *Following page* 497
Editorial 1
EDNSG (European Diabetic Nephropathy Study Group) *Following page* 398
Education – diabetes – evaluation A 52
– insulin treatment */see* Computer; Insulin – treatment/*
Elderly – diabetes in 98b
– mortality – glucose tolerance and 760
Electrocardiogram – diabetes – childhood – power spectral analysis 452
– neuroleptic therapy, effect of – diabetes A 153
Electroencephalography – P300 potentials – hypoglycaemia 828
Eli Lilly/EASD Research Fellowship 1992 *Following page* 1010
Embryo – maternal diabetes – free radicals – rodents A 35
– – GLUT expression – rat A 35
– pre-implantation development – maternal diabetes – insulin 406
Endothelial, Endothelium */see also* Aorta, Artery/*
– cell – aldose reductase mRNA expression – glucose, effect of 730
– – calf pulmonary artery 730
– – hyperglycaemia, effect of – free radicals in A 103
– derived relaxing factor – aorta – streptozotocin-diabetic rat 1011
– – diabetes 771
– function – von Willebrand factor 555
– permeability – insulin, effect of A 18
Endothelin – plasma – diabetes Type 1 – vasodilation A 19
– – microalbuminuria A 170
– secretion – exercise, effect of A 19
– – insulin, effect of A 19
Endotoxin – monocyte activation 160
Energy – expenditure – diabetes – Type 2 – Pima Indians 753
Epidemiology */see also* Mortality/*
– age-period-cohort analysis – diabetes mortality 973
– diabetes – childhood – England A 130
– – Denmark 178
– – incidence – age 15–34
– – Italy A 133, 851
– – Netherlands 139
– – Russia A 130
– – study group */see* EDESG/*
– – Sweden 56, 70
– – Taiwan 973
– – Type 1 56, 70
– – – age – infection and A 25
– – – Bulgaria A 131
– – – Catalonia 267
– – – clustering A 24
– – – Europe A 24
– – – Iceland 880
– – – Ireland A 131
– – – maternal-child blood group incompatibility 671
– – – Netherlands A 130
– – – Portugal A 130
– – – rising incidence 139, 178
– – – Sardinia A 25
– – – seasonality – gender effect A 131
– – – Slovakia A 131
– – – Sudan 645
– – Type 2 56
– – – Finland – elderly A 132
– – – Melanesia A 133
– – – oral contraceptive users 967
– – – Papua New Guinea A 132
– – – South Africa A 133
– hyperinsulinaemia – Chinese in UK A 134
– – Nauru & Tuvalu 534
– islet-cell antibody & Type 1 diabetes – Estonia & Finland A 218
– Westernisation, effect of – Melanesia A 133
Epinephrine */see* Adrenaline/*
Errata 98
Erythrocyte – ATP release – diabetes A 172
– glucose handling – diabetes – metformin A 198
– membrane – diabetes A 54
– rheology – diabetes, abnormalities in – monocyte, activated, role of A 171
Eurodiab *Following page* 906
Exercise – assessment A 164
– diabetes – Type 2 – with diet 340
– energy expenditure – diabetes – Type 1 A 73
– fuel metabolism – fructose *vs.* glucose A 72
– hyperglycaemia following – diabetes – Type 1 A 73

- hyperpnoea – diabetes 425
- nerve conduction velocity, effect on 155
- tolerance – albuminuria, reduced in A 73
- training – glycogen synthase, effect on A 91
- – insulin sensitivity, effect on A 72, A 73
- – islet B-cell function A 109
- – skeletal muscle glucose metabolism A 53

Eye *[see also* Cataract; Retina; Retinopathy; Vision*]*
- diabetic complications – European Association for Study of (EASDEC) 190w
- vitreous oxygen tension – streptozotocin diabetes – Errata 98

F

Family study – diabetes – Type 1 – Finland 70
- – Type 2 – plasma amylin 291, 801

Fat *[see also* Adipose tissue; Diet; Obesity*]*
- distribution – coronary heart disease mortality 464
- – glucose tolerance and 653
- – insulin resistance 785
- – metabolic disturbances A 92

Fatty acid – non-esterified – adrenaline, response to 129
- – growth hormone, effect of – pulsatility 542
- polyunsaturated – dietary *[see also* Diet – fat*]*
- – – diabetes 165

Fertility – diabetes – Type 2 A 133
Fetus – rat – cartilage proteoglycan production – maternal diabetes 517
- umbilical artery velocimetry – maternal diabetes A 180

Finland – diabetes incidence 70
Flow cytometry – fluorescence-activated 436
- human fetal pancreas 436
- light-scatter A 119

Fluorescence-activated cell sorting 436
Foot, diabetic – osteomyelitis – 111In-IgG scintigraphy A 159
- transcutaneous oxygen tension A 173
- ulceration – risk factors A 158, A 159
- – – foot pressures 660
- – treatment A 159

Free radical – defence – diabetes – ascorbic acid, effect of A 167
- islet toxicity A 215
- superoxide – polymorphonuclear cell – diabetes A 10

G

GAD *[see* Glutamic acid – decarboxylase*]*
gag (group-specific antigen) – protein P30 614
Galanin – antagonist – galantide II A 126
Gastric emptying – diabetes – cisapride treatment A 203
- hyperglycaemia, effect of A 5

Gastric inhibitory peptide *[see* GIP*]*
Gastroparesis, diabetic – cisapride, effect of A 6
- erythromycin derivative EM523, effect of A 6

Gene – *reg* – growth factors, effect of 238
Genetics – complications of diabetes – aldose reductase gene A 139
- diabetes S 1w
- – mitochondrial DNA? 1181r
- – twin study – Finland 1060
- – Type 1 *[see also* HLA*]*
- – – familial occurrence A 25
- – – HLA – aetiologic fraction 475
- – – HLA-DQ RFLP 254
- – – insulin-gene region A 137
- – – Japan 419
- – – – *Erratum* 906
- – – manganese superoxide dismutase polymorphism A 71
- – – T-cell receptor gene A 137
- – – tumour necrosis factor gene A 138
- – Type 2 – early onset – glucokinase mutant A 62
- – – glucokinase gene A 139, 632
- – – GLUT *[see also* GLUT*]*
- – – – 1 A 72
- – – – 4 486
- – – insulin receptor tyrosine kinase 486
- – – Mauritius 632
- – – mitochondrial gene A 139
- – – skeletal-muscle glucose-utilisation proteins A 72
- – – South Indians A 140
- heritability – diabetes 1060
- malnutrition-related diabetes 283
- methods – polled multiples single nucleotide primer extension A 71

Geriatrics *[see* Elderly*]*
Germ theory of disease 187
GIP (glucose-dependent insulinotropic peptide)
- endocrine pancreas, effects on – sulphonylurea synergism A 85

Glomerular – charge selectivity – diabetes A 144, A 145
- – glycaemic control, effect of 1165
- function – C-peptide, effect of – diabetes 121
- – diabetes – kallikrein excretion and 857
- – – prostaglandin excretion and 857
- – diabetic rat – sorbinil, effect of 414
- hyperfiltration – prospective follow-up A 70
- mesangial cell – angiotensin II effect – glucose, effect of A 10
- – atrial natriuretic factor, effect of A 10
- – extracellular matrix synthesis – glucose, effect of A 11
- – – paracrine effects A 11
- – heparan sulphate proteogiycan – glucose, effect of 183
- number – diabetes – Type 1 & Type 2 844
- selectivity – assessment – diabetes A 145
- stereology 803, 844
- structure – diabetes – Type 1 803r

GLP-1 (glucagon-like peptide-1) 701r
- (7–36) amide – receptor A 83
- – insulinotropic effect – basal state A 109
- peptides – structure A 109

Glucagon – intranasal 398c
- secretion – catecholamine, effect of A 123
- – glutamate-stimulated A 123
- – muscarinic receptor, effect of – subtype A 105
- – neural influence 1133
- – sympathetic stimulation – diabetic rat 1035
- synthesis 701r

Glucocorticoid – diabetogenic effect – islet glucose cycling A 103
- nocturnal – glucose homeostasis, effect on A 195

Glucokinase – expression – liver *vs.* islet A 138
- gene – cDNA probe 743
- – – *Erratum* 1100
- – diabetes – Type 2 632
- – polymorphism – MODY A 62
- – – MODY A 63

Gluconeogenesis – hepatic – diabetes Type 2 – substrate availability A 106
Glucose – analogue – D-glucose – anomers 505
- autoxidation – diabetic nephropathy, role in 499r
- blood – age effect A 132
- – bimodality – genetic A 132
- – monitoring *[see also* Glucose – sensor*]*
- – – device – Satellite G A 204
- – sampling method – hypoglycaemia 287
- dependent insulinotropic peptide *[see* GIP*]*
- disposal – mathematical model 676
- fluxes – skeletal muscle – mathematical model A 28
- homeostasis – hepatic glucose output, role of A 106
- monitoring – subcutaneous 1177
- production, hepatic – amylin, effect of 116
- – Pima Indians 753
- – vagotomy, effect of A 7
- sensor – blood – fine-needle A 205
- – immune response to A 206
- – microdialysis – subcutaneous 1177, 1087
- – noninvasive – near-infra-red spectrometry A 204
- – subcutaneous 224
- – – calibration *in vivo* A 205
- – – microdialysis A 205
- – – self-tuning A 204
- – membrane – bacterial cellulose A 204
- subcutaneous – continuous monitoring 1087
- tolerance – birth-weight and 444
- – heterogeneity – genetic and anthropometric factors 653
- – impaired – islet B-cell function A 109
- – – mortality 760
- tracer – ^{13}C-labelled – mass spectrometry A102
- – ^{3}H-2-deoxy-D-glucose 310
- transport – hyperglycaemia, effect of – rat muscle A 80
- – insulin-stimulated – phosphodiesterase activation in A 89
- – skeletal muscle – amylin, effect of 26

- transporter */see* GLUT/
- – brain 304
- – endothelium A 18
- turnover – assessment A 27
- – dawn phenomenon 372
- – diabetes – cirrhosis A 37
- – – Type 1 – impaired glucose disposal A 106
- – – Type 2 A 36
- – – – glucagon, role of A 37
- – extended fasting, effect of in man 357
- – hyperglycaemia, effect of – minimal model analysis A 28
- – – insulin, basal, role of A 36
- – lipid metabolism and A 8
- – liver – denervated A 37
- utilisation – lipids, effects of A 7
- – index 310
- – regulation – extended fasting, effect of in man 357

Glucosidase – inhibitor */see* α-glucosidase inhibitor/

Glucotoxicity */see* Insulin – secretion – hyperglycaemia/

GLUT (glucose transporter)
- 2 – expression – insulin & glucose, effects of A 44
- – – islet 1125
- – – liver *vs.* islet A 138
- 3 304
- 4 – expression – diabetes – Type 1 – adipose tissue A 90
- – – – Type 2 143
- – – – – *Erratum* 594
- – phosphorylation, effect of A 90
- – polymorphism – diabetes – Type 2 486
- – spontaneously hypertensive rat 712
- – subcellular distribution – diabetes 456
- – tissue-specific – b_2-adrenergic stimulation, effect of A 53

Glutamic acid – decarboxylase */see also* Antibody – islet-cell – antigen/
- – antigenicity 380
- – expression – glucose, regulation by A 41
- – – insulin secretion rate and 490
- – – islet A, B and D cells A 41
- – two forms A 129

Glutamine – metabolic effects A 7

Glutathione – neuropathy, treatment of – streptozotocin-diabetic rat 813

Glycaemic control – cognitive function during hypoglycaemia 828
- diabetes – Type 2 – assessment – fasting blood glucose A 200
- lysosomal enzymes, plasma 991
- microalbuminuria, effect in 1165
- microalbuminuria and 1049
- retinopathy and 1049

Glycation – advanced end-product – aminoguanidine, inhibition by 96
- end-products – monocyte adhesion 160
- albumin – assay – HPLC 699c
- collagen – aminoguanidine, effect of 19
- – Vitamin E, effect of 913
- diabetic nephropathy, role in 499r
- end products, advanced 19
- fibronectin – vascular smooth muscle adhesion A 54
- haemoglobin */see* HbA_{1c}/
- inhibitor – ascorbic acid A 55
- – D-lysine A 55
- – flavonoid A 55
- LDL 202

Glycogen – metabolism – adrenaline, effect of 399
- placenta 45
- synthase – muscle – hyperglycaemia, effect of – diabetic rat A 53
- – – Type 2 diabetes A 54
- – – diabetes – Type 2 80
- – – diabetes – Type 2 – diet, effect of 777

Glycolysis – adrenaline, effect of 399

Group-specific antigen */see* gag/

Growth */see also* Stature/
- B-cell, pancreatic – diabetes 193r
- factor – insulin-like */see* IGF/
- fetal – glucose tolerance in adult life 444
- hormone – deficiency – dawn phenomenon, absence of 372
- – deficiency – lipolysis normal in diabetes 372
- – GLUT-2 expression, effect on – rat liver A 66
- – insulin resistance due to – route of administration and A 87
- – lipolytic effect – fasting A 8
- – metabolic effects A 20
- – – continuous *vs.* pulsatile administration 542
- – – diabetes – Type 1 542
- – – – Type 2 A 84
- – receptor – B-cell, pancreatic A 22
- – releasing-hormone – glucose homeostasis, effect on? A 105
- – treatment – insulin resistance in A 66
- islet – *reg* gene 238
- pericyte – glucose, effect of – retina *vs.* brain 818
- rate – prediabetes – Type 1 528
- vascular smooth muscle – diabetes – rat 104

GTP binding protein – pertussis-toxin sensitive – insulin secretion A 118
- rab3 – insulin secretion A 12
- regulatable – islet A 12

Guanosine monophosphate – rat islet 1020

Gut motility – diabetes A 6
- hyperglycaemia, effect of A 5

H

Haemostasis – diabetes A 170
- Factor VIII:C – diabetes 863
- plasminogen aactivator – inhibitor A 186
- Thrombin activity – diabetes 863
- von Willebrand factor – diabetic retinopathy 555

Hand ergometer 1151

HbA_{1c} – assay, rapid – desktop A 206
- rapid – immunoturbidometric A 206
- dynamics – fall after return to normoglycaemia 191c

HDL – */see* Lipoprotein – HDL/

Heart – coronary disease – cholesterol synthesis and – diabetes A 167
- – hyperinsulinaemia and 766
- – mortality – diabetes 464
- – – impaired glucose tolerance 464
- coronary perfusion – hyperinsulinaemia A 94
- glucose transporters – phorbol ester, effect of A 89
- ischaemia – silent – diabetes – autonomic neuropathy A 154
- myocardium – GLUT expression – diabetes – rat A 45
- – hyperglycaemia, direct effect of A 94
- rate variability – childhood diabetes 452
- size – diabetes – Type 1 – twin study A 95

Heat – shock protein 60 */see* HSP60/

Height */see* Stature/

Heparan sulphate – proteoglycan – glomerular mesangial cell 183

Hepatocyte – culture – rat – IGF-II action 216

Heterogeneity – diabetes – South India 283

Hexose – monophosphates – skeletal muscle 399

HLA – X – diabetes – Type 1 A 71
- assay – serological *vs.* DNA – diabetes – Type 1 475
- Class I – diabetes – Type 1 – Finland A 135
- – expression – lymphocyte – diabetes – Type 1 A 214
- – islet B-cell, expression by – mumps virus, effect of 63
- Class II – diabetes Type 1 475
- – – Chinese A 136
- – – France A 135
- – – glutamic acid decarboxylase antibodies 996
- – – heterogeneity A 136, A 137
- – – Japan 419
- – – – *Erratum* 906
- – – polyendocrinopathy A 71
- – non-coding region – diabetes – Type 1 A 136
- diabetes – secondary failure of oral hypoglycaemic agent 1159
- DQ */see also* HLA – Class II/
- – diabetes Type 1 254
- – – protection A 137, A 138
- – – Sweden A 136
- – expression – diabetes – Type 1 – Spain 583
- – islet-cell antibody and 570
- – RFLP 254
- DR – prediction of diabetes Type 1 in siblings 955
- genotype – diabetes Type 1 – Finland 70
- haplotype – diabetes Type 1 – Algeria A 135
- – – Finland A 135
- islet-cell antibodies and 550

HMG CoA reductase inhibitor – simvastatin – diabetic nephropathy 447
- – insulin resistance unaffected A 169

HSP60 (heat – shock protein 60)
- related protein – islet B-cell secretory granules 316

Hyperandrogenism – insulin resistance – spironolactone, effect of A 86

Hyperglycaemia – diabetic nephropathy, role in 499r
- glomerular mesangial cell, effect on 183
- postprandial – acarbose, effect of – neuropathy 325

Hyperinsulinaemia – euglycaemic – sympathetic nervous response 873
– genetic and anthropometric factors 653
– prediabetes Type 2 534
– renal function, effect on 1042
Hypertension – Ca^{2+} – cytosolic – bradykinin-stimulated fibroblast A 161
– diabetes – ACE inhibitor treatment A 93
– – Africa A 93
– – hyperinsulinaemia, role of? 873
– – nephropathy A 144
– – Type 2 – sodium homeostasis A 162
– – Type 2 – sympathetic nervous system, role of? 835
– glucose metabolism in A 162
– hereditary hypertriglyceridaemic rat A 161
– insulin, plasma levels A 93
– insulin resistance 294c, 649, 1009b
– risk factor for diabetes A 162
– treatment – diabetes A 163
Hypertriglyceridaemia – insulin resistance – diabetes – Type 2 1140
Hypoglycaemia – autoimmune – immunosuppressive treatment A 187
– blood glucose sampling method 287
– cardiac function A 186
– cerebral adaptation 828
– cognitive function during – previous glycaemia, effect of 828, A 43
– counterregulation – human *vs.* porcine insulin, following A 186
– – insulinoma A 186
– – – following removal A 185
– – liver innervation, role in A 42
– – pancreatic polypeptide A 185
– – threshold reproducibility 958
– diabetes Type 1 A 183
– electroencephalography 828
– glucose production – gluconeogenesis *vs.* glycolysis A 185
– human insulin and 906b
– hyperlactataemia in – skeletal muscle not source A 43
– insulin resistance during – liver A 185
– – skeletal muscle A 182
– nocturnal – alcohol after exercise, role of? A 183
– – cognitive function following 898, A 183
– recovery – electroencephalography A 43
– recurrent severe – cerebral blood flow following A 43
– – cerebral blood flow following A 182
– spontaneous – reactive – insulin sensitivity in A 187
– symptoms – threshold reproducibility 958
– treatment – glucagon – intranasal 398c, A 184
– – theophylline A 184
– unawareness *[see also* Hypoglycaemia – symptoms*]*
– – autonomic neuropathy, unrelated to A 184
– – reversibility A 42
Hypoglycaemic agent – AG-EE 623 ZW A 116, A 200
– new 98b
– oral – α-adrenoceptor blocking – SL 84.0418 A 201
– – α-amylase inhibitor – miglitol A 199
– – benfluorex A 200
– – Chinese traditional A 200
– – CS-045 A 201
– – metformin A 198
– – – distribution A 199
– – – sulphonylurea, combined therapy A 199
– – secondary failure – autoimmunity markers 1159
– – sulphonylurea – glyburide – trial *vs.* insulin A 198
– sulphonamide – history 907r
– – mechanism of action 907r
– sulphonylurea – glibenclamide – non-sulphonylurea moiety A 103
– – islet B-cell, effect on – Na^+ influx A 120
– – – interleukin 1β A 121
– – muscle glucose uptake, effect on A 101
– – receptor, islet B-cell A 38
– – – intracellular location A 110
– – – phosphorylation, effect of A 111
– – T-lymphocyte proliferation, effect on A 214
Hypomagnesaemia 77

I

IAPP (Islet amyloid polypeptide) *[see* Amylin*]*
IGF – I – c-fos transcription, activation of – insulin receptors and A 65
– – glucose turnover, effect on – skeletal muscle A 105
– – isoforms – receptor binding A 83
– – liver – insulin & growth hormone routes, effect of A 84
– – metabolic effects – dog A 84
– – – normal man A 65
– – – Type 1 diabetes A 65
– – vascular smooth muscle, effect on – diabetic rat 104
– II – action – glucose metabolism – rat 932
– – action – hepatocyte 216
– – muscle glucose uptake, effect on A 17
– – recombinant human – rat, metabolic effects in A 84
– binding protein – 1 – diabetic neuropathy 868
– – renal – diabetes – rat 589
Immunity – diabetes, impaired in – BB rat A 215
Immunoassay – enzyme-linked 985
– particle concentration 985
Immunofluorescence – indirect – islet-cell 385
Immunotherapy – diabetes Type 1 1093r, 1096r, 1101r
– – cyclosporin A – young children 884
– – ethics – Errata 98
– – interleukin-2 analogue – DAB486-IL-2 A 218
Incretin – GLP-1 701r
Incretin effect *[see* Diet – fat; Insulin – secretion*]*
Infection *[see also* Virus*]*
– bacteraemia – fatal – diabetes A 142
– Chlamydia – diabetes A 142
Inflammation – autoimmunity and 187
Information technology – diabetes care – study group (DOIT) *Following page* 1100
Instructions to Authors (full version) January & July issues A5
Insulin *[see also* Hyperinsulinaemia*]*
– action – capillary permeability 99r
– analogue – crystal contact engineering A 193
– – fast-acting – B1-glycated A 193
– – – B10Asp – carcinogenicity A 3
– – – B28Asp A 3
– – – near-C-terminal deletion A 4
– – – subcutaneous absorption A 3
– – organ specificity – Glu-A13,B10 A 193
– – prolonged-action A 4
– assay – subcutaneous – microdialysis A 92
– dose adjustment – computer model A 194
– gene *[see also* Genetics*]*
– – non-allelic I & II – differential expression in mouse A 108
– – regulation A 66
– – – Xenopus laevis A 67
– – therapy – somatic cell A 3
– human – hypoglycaemia and 906b
(Insulin) – infusion – device – implantable A 14
– – device – implantable A 196
– – intraperitoneal A 197
– – – access system A 196
– – – device – implantable A 14
– – – long-term A 196
– – portal *vs.* intravenous A 37
– – subcutaneous – cost effectiveness A 196
– – – microalbuminuria, effect on 1165
– injection – device – pen – needle A 197
– intranasal A 14
– – spray angle A 194
– lipid metabolism, effect on – glucose metabolic effect of insulin, role in A 106
– metabolism A 83
– oral – polyalkylcyanoacrylate nanoencapsulated A 4
– plasma – testosterone and 173
– protein synthesis, effect on *in vivo* A 20
(Insulin) – receptor – α-subunit proteolysis – affinity, effect on A 82
– – binding kinetics – biosensor study A 83
– – gene – deletion – insulin resistance A 81
– – – mRNA transcription abnormality 639
– – – mutation 261
– – IGF-II, effect of 216
– – isoforms – Type 2 diabetes A 75, A 76
– – mRNA – splice patterns A 100
– – mutant – type A insulin resistance A 76
– – substrate interaction – structural aspects A 44
– – trophoblast 45
– – tyrosine kinase activity – diabetes – Type 2 – diet effect 777

– – – polymorphism – diabetes – Type 2 486
– – – hypoglycaemia, effect of A 13
– – – hypomagnesaemic rat A 82
– – – natural inhibitor – human A 44
– – – phospholipase C, effect of 109
– – – relatives of diabetes – Type 2 A 88
– – – spontaneously hypertensive rat 712
– – – vanadate, effect of 510
– – up-regulation A 82
– – vanadate, effect of – rat adipocyte 510
(Insulin) – resistance – ageing, with – gender, effect of A 97
– – alcohol 39
– – amylin 291, 801, 297r
– – children of Type 2 diabetics A 68
– – coronary heart disease and – Type 2 diabetes A 68
– – diabetes – Type 1 – microalbuminuria A 95
– – – Type 2 – GLUT-4 143
– – – – – *Erratum* 594
– – – – hypertriglyceridaemia 1140
– – diurnal variation – growth hormone in A 87
– – *fa/fa* rat – vanadate, effect of 522
– – goldthioglucose-obese mouse – pyruvate dehydrogenase A 88
– – hepatic – amylin, effect of 116
– – hypercholesterolaemia A 68
– – hyperglycaemia, effect of 80
– – hypomagnesaemia 77
– – insulin receptor gene mutation 261
– – insulin secretion in – family history of diabetes, effect of A 108
– – mechanism – diabetic rat 310
– – pregnancy 45
– – rat, fat-fed – antiglucocorticoid treatment A 98
– – Type A – insulin receptor mutant 639
(Insulin) – secreting cell */see also* B-cell, islet; Insulinoma/*
– – GLUT-2 – glucose concentration, effect of A 13
– – growth – SRC homology 2 protein, role in A 119
– – growth hormone receptor regulation A 22
– – HIT T15 – Ca^{2+}-activated K^+ channel purification 619
– – inositol triphosphate – receptor A 99
– – malonyl CoA A 13
– – protein phosphatase A 100
(Insulin) – secretion */see also* Amylin; C-peptide; GTP – binding protein; Pulsatility/*
– – ageing, impairment with – diet, effect of A 114
– – amylin, inhibition by A 29
– – – $CGRP^{8-37}$, effect of A 29
– – arachidonic acid, effect of A 38
– – – protein kinase C, role of A 113
– – arginine-induced – hyperinsulinaemia, effect of A 30
– – – nitric oxide A 30
– – catecholamine, effect of A 114
– – – mechanism A 112
– – diabetes – Type 2 A 87
– – exocytosis – action potential, sensitivity to A 122
– – – calcium-dependent A 58
– – glucokinase role A 29
– – – MODY mutants A 29
– – glucose, desensitisation by */see* – hyperglycaemia../*
– – glucose-stimulated – anomeric specificity 505
– – – impaired – arginine, effect of 367
– – – – dexamethasone, effect of 367
– – – membrane potential clamp, despite A 122
– – – neonate, deficient in A 124
– – GLUT expression and A 124, 1125
– – glutamic acid decarboxylase expression and 490
– – glycine, potentiation by A 117
– – GTP, potentiation by – glucose, effect of A 116
– – hyperglycaemia, prolonged, effect of A 125, A 126
– – – diazoxide protection A 112
– – – neural control A 80
– – incretin effect – GLP-1 [7–36 amide/ *vs.* GIP A 39
– – – protein kinase C, role of A 112
– – intracellular metabolism and 482
– – leucine analogues, stimulation by A 113
– – mastoparan, effect of A 116
– – muscarinic receptor, effect of – subtype A 105
– – myotonic dystrophy 1170
– – neural influence 1133
– – neural stimulation A 114
– – nitric oxide, role in – rat islet 1020
– – oscillatory – amplitude modulation of fast insulin transients A 110
– – – diabetes Type 2 – somatostatin, effect of A 38
– – – glucose ingestion, effect of A 38
– – – prediabetes Type 1 32
– – – ultradian – diabetes – Type 2 681
– – oxytocin, effect of A 127
– – phosphatase inhibitor, effect of – okadaic acid A 111, A 112
– – protein kinase C, role of A 113
– – reduced – prediabetes *vs.* endurance training A 108
– – succinic acid methyl esters, stimulation by A 108
– – sympathetic stimulation – diabetic rat 1035
– – vasopressin, effect of A 127
– – VIP, effect of – mechanism A 121
(Insulin) – sensitivity – amino-acid infusion, effect of in man 357
– – pancreas transplantation, following 676
– signalling system – glycosyl-phosphatidylinositol-dependent – *fa/fa* rat A 89
– subcutaneous – absorption kinetics – isophane A 194
– – – pen devices A 197
– synthesis */see* B-cell; Insulin-producing cell; Islet; Proinsulin/*
– transport – transcapillary A 86
– treatment – dawn phenomenon */see* Dawn phenomenon/*
– – intensive – long-term follow-up A 194
Insulinoma – insulin resistance – hypertension, absence of 294c, 649
– – reversibility A 86
– treatment – diazoxide – euglycaemic clamp study A 87
Insulitis – immunohistopathology & HLA Class II expression A 41
– imaging *in vivo* A 214
– nitric oxide cytotoxicity A 216
– NOD mouse – T-cell role 924
Interferon – γ – islet toxicity 409
Interleukin – 1 – diabetes induction – rat A 212
– – islet toxicity 409
– 1β – diabetogenic effect *in vivo* – rat 331
– – hyperglycaemia induced by A 24
– – islet B-cell, effect on – mechanism A 128
– – islet graft failure, role in 231
– – islet toxicity – lysozyme, protection by A 212
– – – protease inhibitor study A 212
– – – protein map study A 212
Ion channels S 23w
IRMA */see* Assay – immunoradiometric/*
Islet */see also* Insulitis/*
– amyloid peptide */see* Amylin/*
– blood flow – neural control A 114
– capillary permeability – BB rat 1118
– cell – human – isolation A 120
– – line A 118
– – replication 193r
– – toxicity – oxygen free radicals 1028
– cryopreservation 89, A 126
– culture */see also* Islet – growth/*
– – human fetal – mumps virus, effect of 63
– GABAA receptor A 22
– glucose oxidation – NOD mouse 924
– GLUT-2 – expression 1125
– – mRNA expression – regulation A 22
– glutamic acid decarboxylase 380
– – expression – insulin secretion rate and 490
– growth – attachment, effect of A 124
– – basic fibroblast growth factor, role of A 123
– – hyperinsulinaemia, inhibition by A 125
– human – transplantation 89
– interleukin 1, effect of – biotinylated oligonucleotide probe study A 211
– isolation – collagenase 735
– – protease 735
– lactate production A 125
– metabolism – MTT (tetrazolium) colorimetric assay 482
– neural control – non-adrenergic non-cholinergic 1133
– nuclear DNA-protein complex, glucose-sensitive A 66
– oncogenes A 21
– rat – nitric oxide 1020
– repair – DNA-damage inducible genes A 127
– replication – *reg* gene – growth factors 238

K

Kallikrein – renal excretion – diabetes – Type 1 857
– urinary – diabetes A 145

Ketoacidosis – Eurodiab study A 183
– Sudan 645
Ketogenesis – adrenaline-induced – insulin, effect of 129
Ketone bodies – growth hormone, effect of – pulsatility 542
– metabolism – adipose tissue A 8
Kidney *[see also* Glomerular*]*
– blood flow – C-peptide, effect of 121
– dopamine excretion – diabetes A 146
– endothelin-1 expression – streptozotocin-diabetic rat A 12
– function – insulin, exogenous, effect of 1042
– – transtubular potassium gradient – diabetes A 146
– hypertrophy – diabetes – IGF-binding protein 589
– magnetic resonance imaging – diabetes 1002
– tubule – function – diabetes 857
Kinetic analysis – apolipoprotein A metabolism 347

L

Labour – glucose turnover during A 177
LDL *[see* Lipoprotein*]*
Lecture – Golgi – diabetic neuropathy 2r
Lens – β-crystallin – diabetes, oxidation in – ascorbic acid, effect of A 143
Leucine – insulin secretion, stimulation of *[see* Insulin – secretion – leucine*]*
Life-table – risk of Type 1 diabetes in siblings 955
Limited joint mobility *[see* Cheiroarthropathy*]*
Linoleic acid – dietary – microalbuminuria 165
Lipid – bilayer – planar – Ca^{2+}-activated K^+-channel assay 619
– cholesterol – metabolism – menstrual cycle, effect of A 167
– peroxidation – diabetes – vitamin E and ascorbic acid, effects of A 201
Lipolysis – adrenaline-induced – insulin, effect of 129
– diabetes – Type 1 – growth hormone deficiency, normal in 372
Lipoprotein – A – microangiopathy, diabetic A 168
– apolipoprotein *[see* Apolipoprotein*]*
– apolipoprotein-B-containing – nephropathy – diabetic A 64
– diabetes – diet – polyunsaturated fatty acid 165
– diabetic nephropathy – simvastatin treatment 447
– HDL – metabolism – diabetes – Type 1 347
– LDL – gemfibrozil, effect of – diabetes A 168
– – metabolism – diabetes 202
– metabolism – postprandial – diabetes – Type 2 A 168
– VLDL – diabetes, abnormal in A 64
– – metabolism – HDL metabolism and – Type 2 diabetes 347
Lithium – clearance – insulin, effect of 1042
Liver – 6-phosphofructo-2-kinase – diabetic rat – vanadate, effect of 243
– isolated perfused – amylin, effect of 116
Lung *[see* Pulmonary*]*
Lymphocyte – T – clone – diabetes – Type 1 A 33
– – NOD mouse insulitis 924
Lysosome – enzymes – plasma – diabetes 991

M

Magnesium – plasma – diabetes Type 2 77
– – interpretation 904c
Magnetic resonance imaging 1002
Malnutrition – maternal – diabetes Type 2 pathogenesis 595r
Mass spectrometry – stable isotope-labelled glutamate A103
Matrix – extracellular – collagenase & protease, effects of 735
Metabolic control – diabetes *[see* Glycaemic control*]*
Metabolism & Insulin Action Study Group *Following page* 296
Metformin – GLUT-4, effect on – rat adipocyte A 90
Microalbuminuria – albumin excretion rate, prediction by A 70
– apolipoprotein A and – diabetes – Type 2 1055
– blood pressure and – childhood A 70
– cardiovascular risk factor A 134
– – endothelial dysfunction A 170
– diabetes – ACE inhibitor *vs.* calcium-channel blocker A 149
– – diet – polyunsaturated fatty acid 165
– – prospective follow-up A 60, A 61
– – glomerular charge selectivity 1165
– prevalence – diabetes – Norway 1049
– tubular albumin reabsorption and A 11
Microangiopathy – diabetes 803r
– – lysosomal enzymes 991
– – myo-inositol and A 172
– – pathogenesis 499r
Microdialysis 664
Military medicine – diabetes incidence 139
Milk – cow – protein – antibodies 980
Minkowski – Lecture 1991 1101r
– Prizewinner 1992 – Van Schaftigen, E *Following page* 1010
Mitochondrial DNA – diabetes pathogenesis, role in? 1181r
Model, mathematical – continuous infusion of glucose (CIGMA) A 28
MODY (Maturity-onset diabetes in youth) – genetics – glucokinase mutant A 62
Monocyte *[see also* Adhesion*]*
– activated 160
– glycated collagen adhesion 160
Mortality – alcohol-related – glucose intolerance and 39
– coronary heart disease – body fat distribution 464
– – Finland A 34
– – glucose tolerance 464
– diabetes – alcohol-related deaths 39
– – diet, effect of – Northern Ireland A 134
– – elderly men 760
– – Type 1 – Japan A 33
– – – Norway A 34
– – – Sudan 645
– – – UK A 33
– suicide – diabetes – Type 1 A 34
– trend – diabetes – Taiwan 973
Mouse – gold-thioglucose obese – glucose turnover A 104
– hyperglycaemic – transgenic insulin receptor ectodomain A 48
– NOD (non-obese diabetic)
– – anti-idiotype antibody – islet-cell-antibody-reactive – effect of A 217
– – cell-mediated autoimmunity A 213
– – diabetes – anti-complement activity A 207
– – – BCG vaccination, effect of A 217
– – – T-cell role 924
– – glutamic acid decarboxylase autoimmunity, role of A 48
– – immunomodulation – linomide A 49
– – insulitis – calcitriol, protection by A 217
– – interleukin 1β mRNA – islet content A 211
– – islet B-cell – retrovirus gag protein P30 614
– – – granule – HSP60 distribution 316
– – T-lymphocyte vaccination A 216
– *ob/ob* – islet – monoamine oxidase activity A 78
MTT (tetrazolium) assay 482, 1028
Mumps virus 63
Muscle – respiratory – mechanical load – diabetes 425
– skeletal – capillary diffusion capacity – C-peptide effect 1151
– – glucose disposal – athletes A 53
– – glucose transport – amylin, effect of 26
– – glucose uptake – diabetes – Type 2 – diet effect 777
– – GLUT-4 – subcellular distribution 456
– – glycogen synthase – hyperglycaemia, effect of 80
– – metabolism – adrenaline, effect of 399
– – – C-peptide effect 1151
– smooth – growth – insulin & IGF-I, effects of 104
Myotonia – Steinert's atrophic – insulin-receptor dissociation kinetics A 82
Myotonic dystrophy – hyperproinsulinaemia 1170

N

Nauru – hyperinsulinaemia predicting diabetes Type 2 534
Neonate – birth-weight – adult glucose tolerance and 444
– birth-weight – IGF and A 178
– C-peptide – maternal diabetes A 181
– hypoglycaemia – counterregulation A 181
– islet function – rhesus haemolytic disease A 181
Neonate – maternal diabetes – islet – morphology A 35
Nephropathy, diabetic – ACE inhibitor – renal functional reserve A 149
– advanced – coronary heart disease A 96

- aminoguanidine, effect of – rat 96
- apolipoprotein B RFLP A 59
- blood pressure – circadian variation 1074
- childhood A 69
- European Study Group *[see* EDNSG*]*
- genetic factors – Type 2 diabetes A 61
- glomerular changes 803 r
- glomerular charge selectivity 1165
- hypercholesterolaemia – simvastatin treatment 447
- hypertension – ACE inhibitor *vs. b*-blokking agent A 148
- – treatment, effect of A 147
- magnetic resonance imaging of kidneys 1002
- mesangial-cell heparan sulphate proteoglycan 183
- pancreatic transplantation, effect of A 74
- pathogenesis 499 r, 803 r
- – *Erratum* 1100
- prediction A 70
- progression – factors affecting A 147
- – Type 1 *vs.* Type 2 diabetes A 61
- prorenin, plasma A 146
- study group (EDNSG) *Following page* 1100
- urokinase excretion A 145

Nerve – aminoguanidine, effect of – streptozotocin-diabetic rat A 151
- biopsy 2 r
- blood flow – diabetic neuropathy 1113
- conduction – tissue oxygenation, effect of – diabetes 1146
- – tissue oxygenation, effect of – diabetes A 16
- velocity – exercise, effect of – diabetic neuropathy 155
- immunohistochemistry – neuropathy – diabetic 889
- injury – VIP response – diabetes A 150
- microangiopathy A 158
- morphometry 560
- – diabetic neuropathy A 157
- Na^+/K^+ ATPase – cAMP, regulation by A 150
- – phosphorylation – protein kinase A 149
- optic – diabetes – BB rat 602
- sudomotor – function – diabetes 889

Nervous system *[see also* Astrocyte*]*
- neurotrophic interactions S 18 w

Netherlands – diabetes incidence 139

Neurodiab (Diabetic Neuropathy Study Group) *Following pages* 192 w, 497

Neuropathy *[see also* Olfaction; Taste*]*
- assessment – glycaemia, effect of A 15
- autonomic 2 r
- – electrocardiography – QT-interval A 152
- diabetic 2 r
- – $ACTH^{4-9}$, effect of A 16
- – aminoguanidine, effect of – streptozotocin-diabetic rat 946
- – animal model – streptozotocin-diabetic rat 813
- – assessment – single-fibre electromyography A 157
- – – sural nerve morphometry 560, A 16
- – autonomic – assessment A 152, A 47
- – – – baroreflex sensitivity index A 152
- – – – computerised A 153
- – – – postprandial hypotension A 154
- – – – ventilatory responses A 155
- – – blood pressure, nocturnal A 48
- – – cardiac – positron emission tomography A 47
- – – childhood 452
- – – gastrin and diamine oxidase activity A 6
- – – glycaemic control, improved, effect of A 157
- – – gut motility A 5
- – – hypotensive effect of insulin A 47
- – – left ventricular mass increased A 47
- – – nerve growth factor in A 48
- – – prevalence A 152
- – BB rat – acarbose, effect of 325
- – exercise nerve conduction test 155
- – foot pressures 660
- – glutathione, effect of A 150
- – glutathione – treatment 813
- – glycaemic control, effect of A 15
- – histopathology 560
- – IGF-binding protein 1 levels 868
- – impotence A 155, A 156
- – nerve growth factor, role of – islet transplantation study A 188
- – nifedipine, effect of 1113
- – oxidative stress, role of 813, A 150
- – painful – pathology A 157
- – postprandial hyperglycaemia, role of – BB rat 325
- – progression – electrophysiological studies A 149
- – selective – Charcot arthropathy 148
- – small-fibre studies 889
- – Study Group (Neurodiab) *Following page* 192 w
- – study group *[see* Neurodiab*]*
- – tissue oxygenation, role of 1146
- – Type 1 vs. Type 2 diabetes 690, 1099 c
- – unmyelinated nerve A 16
- – – function A 154
- – visual evoked potential 602

Nicotinamide *[see also* B-cell, islet – regeneration; Immunotherapy*]*
- diabetes Type 1 A 202, A 203
- – nicotinic acid comparison A 218
- growth, impairment of – rat A 202
- insulin secretion, effect on A 217
- islet-cell protection 1028

Nicotinic acid – analogue – acipimox A 169
- islet protection A 129

Nitrate – vasodilatation – diabetes 771

Nitric oxide – aorta – streptozotocin-diabetic rat 1011
- insulin secretion, not involved in – rat islet 1020
- islet B-cell toxicity 796 r
- synthase – methylguanidine, inhibition by A 79

Nuclear magnetic resonance *[see* Magnetic resonance imaging*]*

Nutrition – diabetes – study group (DNSG) *Following page* 1100
- early life – cow's milk – risk of diabetes – Type 1 980
- – diabetes – Type 1 A 25
- – pancreatic B-cell mass, effect on – rat 939

O

Obesity *[see also* Body – weight; Diet; Fat – distribution*]*
- abdominal – IGF-1 A 69
- – Type 2 diabetes risk A 68
- energy expenditure 753
- glucose homeostasis A 94, 653
- hyperinsulinaemia and – body fat distribution 785

Olfaction – diabetes A 156

Oncogene – rhombotin – glucagon-secreting cell A 21

Oral Hypoglaemic agent *[see* Hypoglycaemic agent*]*

Osteoporosis *[see also* Bone*]*
- prediction – diabetes A 192

Oxidative stress – diabetes – ascorbic acid, affect of A 202
- diabetes – desferrioxamine, affect of A 202

Oxygen – consumption – exercise & diet, effect of – Type 2 diabetes 340
- free radical – cytokine effect on islets, involved in 409
- – islet-cell damage 1028

P

Pancreas – dorsal – agenesis A 141
- exocrine – function – diabetes – Type 1 A 141
- – ganglioside carbohydrate antigen – glycaemic control A 141
- fetal – endocrine precursor cell A 119
- human fetal – amylin immunoreactivity 272

Pancreastatin – insulin-secreting cell, effects on A 76

Pancreatectomy – partial – insulin secretion abnormalities 505

Pedobarography – optical 660

Pericyte – growth – glucose, effect of – retina vs. brain 818

Phlorizin 310

Phosphofructokinase 243
- muscle – Type 2 diabetes A 54

Phospholipase C – insulin receptor kinase, effect on 109

Pima Indians – energy expenditure 753

Pituitary – adenylate cyclase activating peptide – insulin secretion, effect on A 122

Plasma – volume – insulin, effect of 99 r

Plasminogen activator inhibitor – insulin resistance and A 9
- myocardial infarction reperfusion A 9

Platelet – diabetes A 171
- membrane fluidity – diabetes A 172

Platinum – islet B-cell toxicity A 49

Plethysmography – venous occlusion 771

Polyendocrinopathy – islet-cell antibody heterogeneity 385

Polymorphism – glucokinase gene 632, 743
- – *Erratum* 1100
- restriction fragment length *[see* RFLP*]*
- single-stranded conformational – insulin resistance 261

Polyol pathway – diabetic nephropathy, role in 499 r

– nerve – diabetic rat – aminoguanidine, effect of 946
Power spectral analysis 452
pp 185 109
Prediabetes – Type 1 – follow-up A 32
– – growth rate increased 528
– – immunology A 32
– – islet B-cell function 277
– – islet-cell antibody subtypes 385
– – oscillatory insulin secretion 32
– Type 2 – insulin secretion – glucose *vs.* arginine-stimulated 367
Prediction – diabetes – Type 1 1068
– – – glutamic acid decarboxylase antibody 570, A 51
– – – growth-rate 528
– – – insulin autoantibodies 550
– – – islet-cell antibody 550
– – – – subtypes 385
– – – siblings 955
– – Type 2 – hyperinsulinaemia 534
– – – parents & offspring A 129
– disease – consequences S 60w
– insulin dependence – diabetes, newly-diagnosed A 210
Pregnancy *[see also* Embryo, Fetus, Labour, Neonate, Placenta, Teratogenesis*]*
– care – Poland A 180
– diabetes – gestational A 179
– – – amylin A 179
– – – autoimmunity A 211
– – – insulin secretion A 178
– – – leucine flux A 177
– – – microalbuminuria A 178
– – – post-partum glucose tolerance A 179
– – – rat model A 35
– – – screening A 178
– – hypoglycaemia – embryo, effect on – rat A 36
– – insulin treatment – computer-assisted analysis A 180
– – offspring, adult – diabetes A 36, A 182
– – outcome studies A 26
– – preconception care A 26
– – Study Group (DPSG) *Following page* 192w
– – trophoblast insulin binding 45
– glucose homeostasis – ethnic groups A 180
– glucose metabolism A 26, A 27
– IGF – binding proteins – diabetes A 182
– insulin resistance – mammary gland, reduced in A 177
– microalbuminuria – diabetes A 181
– protein metabolism A 177
Proglucagon – 78–107amide 701r
Proinsulin – assay – diabetes – Type 2 469
– assay – ELISA – double-antibody A 117
– conversion – hyperglycaemia, effect of – rodent A 111
– converting enzyme – carboxypeptidase A 67
– – endopeptidase *[see also* Chromogranin*]* A 67
– – – substrate sequence, effect of A 107
– myotonic dystrophy, hypersecretion in 1170
– products – diabetes – Type 2 469
Prosomatostatin – conversion – products A 123
Prostaglandin – E1 – analogue – OP1206.αCD A150
– renal excretion – diabetes – Type 1 857
Protease – islet isolation, use in 735
Protein – kinase C – insulin secretion, role in A 113
– metabolism – diabetes – insulin delivery route, effect of A 21
– – liver transplantation, following A 21
– – skeletal muscle – NEFA, effect of A 20
Psammomys obesus – proinsulin conversion A 111
Pulmonary function – diabetes – Type 1 1173
Pulsatility – growth hormone – metabolic effects 542
– insulin secretion 32
– – ultradian – diabetes – Type 2 681
– insulin infusion – adipocyte, effects on A 88
Pyruvate dehydrogenase – adipose tissue – nutritional control A 167
– kinase – activator A 91
– starvation, effect of A 91

Q

Quality of care – diabetes 429

R

Rabbit – alloxan-diabetic 202
Rat – BB – cell-mediated autoimmunity A 213
– – diabetes – body-weight, juvenile, effect of A 77
– – – genetics A 77
– – – insulin therapy A 77
– – – islet microcirculation 1118
– – – sulphonylurea, prevention by A 23
– – – neuropathy – acarbose, effect of 325
– – – visual evoked potential 602
– – islet-cell antibody – glutamic acid decarboxylase – ELISA A 207
– – – specificity A 207
– – MHC – Class II – islet B-cell expression A 110
– – *reg* gene expression A 140
– – T-cell subsets A 215
– – Travel Fellowship 1010
– diabetes – hereditary *vs.* acquired – islet glucose metabolism A 78
– *fa/fa* – amylin secretion – perfused pancreas A 81
– GK – diabetes, non-insulin-dependent – islet function A 77
– – – insulin receptors, liver A 78
– Long Evans Tokushima Lean – insulitis A 216
– pancreas – isolated – neural mechanisms 1133
– sand – Israel – diabetes, non-insulin-dependent – phospholipid composition A 78
– spontaneously hypertensive 712
– – insulin receptor tyrosine kinase & GLUT-4 A 45
– – insulin secretion & action A 91
– – streptozotocin diabetic 96
– streptozotocin-diabetic – albuminuria – sorbinil, effect of 414
– – angiotensin converting enzyme inhibitor in 12
– – aorta 1011
– – collagen glycation 19
– – insulin resistance – mechanism 310
– – islet stimulation by sympathetic activation 1035
– – islet transplantation 719
– – neuropathy 813
– – – nifedipine effect 1113
– – pregnancy – blastocyst development 406
– – renal IGF-binding protein 589
– – retinal function 624
– – teratogenesis 517
– very-low-dose-streptozotocin-diabetic – insulin action 208
– Wistar Kyoto – normal – interleukin 1*b*, betacytotoxic effect of 331
Reaven's syndrome 595r
– alcohol and 39
– calcium homeostasis A 98
– hypercholesterolaemia, isolated, not included A 97
– hypertension in A 96
– lipoproteins A 96
– statistical appraisal 696c, 697c
Renal *[see* Kidney*]*
Research – diabetes – Europe *Following page* 802
Respiration *[see also* Pulmonary*]*
– effort – diabetes 425
Retina – blood flow – autoregulation – hyperglycaemia, effect of A 143
– capillary permeability – LDL toxicity A 46
– diabetes – early abnormalities 624
– GTP-binding proteins – diabetic rat 624
– pericyte – growth – glucose, effect of 818
Retinopathy, diabetic – aldose reductase inhibitor trial A 45
– childhood A 142
– – predictive markers A 142
– diabetes Type 1 with onset in infancy A 45
– prevalence – Norway 1049
– von Willebrand factor 555
RFLP (restriction fragment length polymorphism) – HLA – DQ 254
Rheology – diabetes – granulocyte deformability A 172
Risk factors – cardiovascular – diabetes – Type 1 A 69
– – diabetes – Type 1 – Europe A 51
– – family history of diabetes A 93
– – glucose tolerance and A 59
– – hyperinsulinaemia? 766
– – insulin, plasma level A 94, 173
– – intervention study A 60
– – nephropathy, diabetic A 59
– – Type 2 diabetes, predictors of A 60
– diabetes *[see also* Prediction*]*
– – Type 1 – Sweden 671

S

Saint Vincent Declaration 429, A 174
Seven Countries Study – mortality – glucose tolerance, effect of 760
Sex – diabetes – Type 1 – growth-rate 528
– ratio – diabetes incidence 139, 56
Sialic acid – serum – diabetes – Type 2 – retinopathy A 143
Simvastatin *[see* HMG CoA reductase inhibitor*]*
Skin – nerve – immunohistochemistry & function 889
Sleep – hypoglycaemia, effect of 898
Smoking – behaviour therapy A 161
– diabetes – glycaemic control and A 160
– – nephropathy A 160
– insulin resistance A 160
– prevalence – assessment A 160
Sodium – excretion – diabetes – dopamine involvement A 147
– – insulin, exogenous, effect of 1042
– transport – erythrocyte A 57
– – Na^+/H^+ – diabetes A 56
– – – gene – proximal tubule A 56
– – – obesity A 56
– – Na^+/Li^+ – diabetes – hereditary component A 57
Somatostatin *[see also* Prosomatostatin*]* 701r
– secreting cell – line A 118
– secretion – neural influence 1133
– – sympathetic stimulation – diabetic rat 1035
Sorbinil *[see* Aldose – reductase – inhibitor*]*
Sreptozotocin – diabetes – thio-D-glucose, prevention by A 23
– very low dose – diabetes Type 2 model 208
Starvation – gluconeogenesis A 102
Stature – adult – glucose tolerance and 698c
– glucose tolerance and 191c
Stress – psychological – glycaemic control of diabetes, effects on A 176
– – metabolic effects of – diabetes Type 2 835
Structural biology & diabetes S 69w
Sweden – diabetes incidence 56
– – *Erratum* 296
Sympathetic nervous system – activation – diabetes – Type 2 835
– diabetes – non-insulin-dependent – rat A 79
– hyperinsulinaemia, effect of 873
– islet function, effect on – diabetic rat 1035
Syndrome X *[see* Reaven's syndrome*]*

T

Tablet treatment of diabetes *[see* Hypoglycaemic agent*]*
Taste – diabetes, impaired in A 156
Telecom Study – insulin resistance – testosterone and 173
Teratogenesis – diabetes – cartilage proteoglycan production 517
Testosterone – plasma – insulin resistance and 173
Tetrazolium salt – islet glucose metabolism assay 482
Thrifty phenotype hypothesis 595
Transplantation – islet *[see also* Islet – isolation*]*
– – bioartificial pancreas – immobilised haemoglobin A 187
– – donor islet mass 719
– – encapsulation – Biopore membrane A 189
– – – oxygen distribution A 188
– – – reinnervation A 188
– – graft mass increased by metabolic demand A 187
– – immune tolerance induction – anti-CD25 therapy A 189
– – insulin infusion therapy following A 190
– – long-term follow-up 89
– – microencapsulation – biocompatibility A 190
– – – cytokines & graft failure 231
– – – macrophage activation A 188
– – partial insulin deficiency following A 190
– – pregnancy, effect of A 189
– – recipient site – rat isograft 917
– – Study Group *[see* AIDSPIT*]*
– kidney with pancreas – quality of life following A 75
– pancreas 494r
– – autonomic neuropathy, effect on A 75
– – benefit assessment 1187c, 1188c
– – cyclosporin A – graft establishment, impairment of A 189
– – diabetic nephropathy, effect on A 74
– – glucose tolerance following A 74
– – insulin sensitivity following 676
– – storage A 74
– – venous diversion, effect of A 190
Transporter *[see also* Glucose – transporter; GLUT*]*
– proteins – adipocyte – immunogold labelling A 88
Treatment – diabetes S 8w
Triglyceride – plasma – coronary heart disease mortality 464
Trophoblast – insulin binding 45
Tumour necrosis factor *[see also* Cytokine; Genetics*]*
– islet toxicity 409
– – fetal A 128
Tuvalu – hyperinsulinaemia predicting diabetes Type 2 534
Twin study – diabetes – Finland 1060
– – Type 2 – concordance rate A 139
– prediabetes Type ! – islet B-cell function – 277

U

Urine – Tamm-Horsfall glycoprotein – diabetes – rat A 80

V

Vanadate – glucose metabolic effect, hepatic – mechanism A 18
– insulin binding, enhancement of – rat adipocyte 510
– insulin resistance, effect on – *fa/fa* rat 522
– liver, effect on – diabetic rat 243
– liver enzyme expression, effect on A 44
Vascular disease – peripheral – glucose tolerance A 95
Vasomotor responses – atrial natriuretic factor – diabetes A 144
– diabetes 771
– – microalbuminuria – nitric oxide and A 19
– – polyol pathway, role of 1011
– – Type 1 A 9
– hyperglycaemia, effect of A 9
– – mechanism 725
– neuropeptide Y, effect of A 79
Venous – compliance – diabetes A 162
Virus – Coxsackie B – diabetes – Type 1 249
– mumps – islet B-cell, effect on – HLA Class I expression 63
– retro- – gag protein p30 – NOD mouse islet B-cell 614
Visual – evoked potential – diabetes – BB rat 602
Vitamin – C *[see* Ascorbic acid; Glycation*]*
– E – diabetes A 202
– – supplementation in Type 2 diabetes A 166
– – thermal stability of collagen, effect on 913
– supplementation – diabetes A 201
Von Willebrand factor *[see* Haemostasis*]*

W

War – glycaemic conrol of diabetes, effect on A 176
Wasp venom – mastoparan – insulin secretion, effect on A 116

X

Xanthine – oxidase – oxygen free radical generation – islet-cell damage 1028